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ERCC1-XPF is a mammalian structure-specific endonuclease that incises at the junction of 
double and 3’-single-stranded DNA. ERCC1-XPF and its homologs are implicated in multiple 
DNA repair pathways including, nucleotide excision repair, interstrand crosslink repair, double 
strand break repair, repair of AP sites, and telomere maintenance, making it essential for 
viability. The pleiotropic phenotypes of ERCC1-XPF deficiency in humans, range from the 
cancer-predisposition syndrome xeroderma pigmentosum to the XPF-ERCC1 progeroid 
syndrome, a disease of accelerated aging. 
This document concentrates on dissecting the role of ERCC1-XPF in crosslink repair, 
elucidating the mechanisms underlying the dramatic phenotypic differences in patients with 
inherited XPF mutations, and exploring the utility of ERCC1 and XPF as biomarkers of tumor 
prognosis. 
Ercc1 and Xpf knockout mice are phenocopies, illustrating that the two proteins function 
exclusively as a heterodimer. These models present a progeroid phenotype, reflected in some 
patients with XPF or ERCC1 mutations. We hypothesize that this accelerated aging is 
consequent on a failure to repair crosslinks, which are highly cytotoxic DNA lesions. The 
crosslink repair mechanism in animals remains poorly elucidated and the exact relationship of 
ERCC1-XPF to other players in this pathway, largely unexplored. Herein we show that ERCC1-
XPF functions in the same pathway of crosslink repair as the Fanconi anemia proteins and that 
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crosslink unhooking by ERCC1-XPF is required for the efficient binding of FANCD2 to the 
chromatin. 
The pleiotropy of phenotypes associated with human ERCC1-XPF deficiency is puzzling. 
Often, the severity of phenotype does not correlate with the DNA incising ability of the mutant 
proteins. We show here that the phenotypic heterogeneity is at least partially explained by the 
mislocalization of mutant proteins to the cytoplasm.  
The public health importance of this work comes from the increasing interest in the 
regulation of ERCC1-XPF expression and activity, due to its involvement in DNA repair 
pathways implicated in the resistance of tumors to platinum-based chemotherapy. A panel of 
antibodies was tested extensively and optimized for use in clinical measurement of ERCC1-XPF. 
This will facilitate improved measurement of DNA repair proteins in clinical specimens and 
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1.0  INTRODUCTION 
ERCC1-XPF is a structure-specific endonuclease initially discovered for its role in nucleotide 
excision repair (NER), a DNA repair pathway that removes helix distorting lesions from the 
nuclear genome (Sijbers et al., 1996a). ERCC1-XPF and its homologs in yeast, Drosophila and 
plants have been found to function in a plethora of DNA damage repair and tolerance 
mechanisms. Humans and mice deficient in ERCC1-XPF show symptoms of accelerated aging 
and predisposition to cancer (Niedernhofer et al., 2006). This makes ERCC1-XPF deficient cells 
and organisms attractive models for the study of mechanisms and treatment of age-related 
degenerative disorders and cancer. 
1.1 PUBLIC HEALTH RELEVANCE 
As the average life expectancy increases, cancers and other age-related disorders escalate in 
prevalence. This can create a significant burden on health care and the economy. Although the 
treatment of early stage cancers and their outcome has improved over the past decades, for many 
types of cancers, especially for cancers at later stages, the survival rates have not improved over 
the last decade (Jemal et al., 2009). Chemotherapy and radiotherapy are used in surgically non-
resectable cases as the treatment of choice. Resistance to chemotherapy is common, especially 
for platinum-based chemotherapy, which is the workhorse of chemotherapies (Modesitt and 
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Jazaeri, 2007). In many cases, this method of treatment does not improve overall patient survival 
(Armstrong, 2002; Jemal et al., 2008; McGuire et al., 2002).  It is therefore of great importance 
to identify the mechanisms behind chemotherapy resistance and to find a way to either 
circumvent these or to tailor the chemotherapy for the best outcome in each individual case. 
Many of the chemotherapeutic drugs including platinum derivatives (Eastman, 1987) and 
radiotherapy (Ward, 1988) act through their ability to damage genomic DNA. It therefore 
follows that the efficiency of DNA damage repair mechanisms could act as a predictor of 
sensitivity to these therapies. As far as the chemotherapy with crosslinking agents such as 
platinum derivatives, nitrogen mustards and mitomycin C (MMC) is concerned, ERCC1-XPF is 
extremely important for both pathways – nucleotide excision repair (NER) and interstrand 
crosslink (ICL) repair – required for tolerance to these drugs (De Silva et al., 2000; Sijbers et al., 
1996a). Therefore, it is important to study the mechanism of action of ERCC1-XPF in these 
pathways. 
Age-associated diseases, such as cardiovascular disease, Alzheimer’s disease, diabetes, 
osteoporosis, hearing and visual impairment, arthritis and cancers, accompany aging. For many 
of these diseases, age is the single most important risk factor. People over the age of 65 years 
have a 10-fold higher risk of cancers compared to their younger counterparts (Finkel, 2005). 
Many of these diseases show a similar trend with advancing age (Kirkwood, 2005) and seem to 
increase exponentially with a linear increase in age (Finkel, 2005). By 2030 the number of 
people above 65 in the US will nearly double and their proportion in the population will go up 
from about 12% to greater than 19% (Greenberg, 2008). Thus, over the next decades, treatment 
of age-associated diseases can make a significant impact on the health care system and the 
national economy. Therefore, it is important to understand the mechanisms regulating and 
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causing the process of aging. The foremost theory is the stochastic theory of aging, which states 
that the organism ages as a result of an accumulation of cellular damage due to genomic 
mutations, mitochondrial dysfunction, damage to proteins and DNA due to endogenous and 
exogenous genotoxic agents, telomere shortening and accumulation of waste products 
(Kirkwood, 2005). Thus, DNA repair plays an important role in the process of aging, 
highlighting the importance of deciphering DNA repair mechanisms. Ercc-/- mice have a 
progeroid phenotype (Niedernhofer et al., 2006), while a milder depletion of ERCC1-XPF leads 
to cancer (Sijbers et al., 1996a). Studying ERCC1-XPF therefore allows us to study both aging 
and cancer, two processes that are responsible for considerable morbidity and mortality in the 
general population. 
1.2 XPF FAMILY MEMBERS 
ERCC1-XPF is a member of the XPF family of endonucleases. The XPF family has no known 
homologs in bacteria (Aravind et al., 1999). It likely arose in archaea, in which there is just one 
family member, Hef (Figure 1-1) (Komori et al., 2002).  The N-terminal region of the XPF-
family shows similarities to the archaeal superfamily 2 (SF2) RNA helicases, and the C-terminal 
region has a conserved (V/I)ERKX3D nuclease motif similar to SF2-helicases (Sgouros et al., 
1999). Euryarchaeal Hef orthologs retain the DExH helicase motif (Komori et al., 2002), though 
crenarchaea, e.g., Aeropyrum pernix and Sulfolobus solfataricus, do not (Figure 1-1) (Nishino et 
al., 2003). Eukaryotic XPF homologs show conservation of the N-terminal half without 
conservation of the DExH motif itself and are therefore, helicase inactive (Sgouros et al., 1999). 
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Figure 1-1: Homologs of ERCC1-XPF 
Homologs of XPF and ERCC1 in various model organisms ranging from bacteria to vertebrates 
 
In eukaryotes, the functional homolog is the ERCC1-XPF heterodimer, with XPF 
retaining the nuclease motif, whereas in archaea, Hef homodimerizes. ERCC1-XPF is highly 
conserved throughout evolution and all eukaryotes studied so far have homologs of ERCC1-XPF 
(Figure 1-1). The eukaryotic XPF has three major domains: a DExH helicase-like domain, an 
ERKX3D nuclease domain and a helix-hairpin-helix like domain (Figure 1-2) (Aravind et al., 
1999; Sgouros et al., 1999). ERCC1, the smaller of the two partners, does not have the helicase-
like domain and has lost its nuclease motif through gene divergence (Gaillard and Wood, 2001). 
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It only has two domains: the central domain, which is nuclease-dead and the C-terminal HhH2 
domain (Figure 1-2), which interacts with the corresponding domain of XPF (de Laat et al., 
1998b). The heterodimeric interaction of ERCC1 and XPF stabilizes these proteins in vivo 
(Niedernhofer et al., 2006). Consequently, XP-F cells have a reduced expression of ERCC1 
(Biggerstaff et al., 1993; Yagi et al., 1997), which is restored by the expression of exogenous 
wild-type XPF (Yagi et al., 1998), and Ercc1 mutant cells have a reduced level of XPF, which is 
restored by exogenous expression of ERCC1 (Houtsmuller et al., 1999).  ERCC1-XPF is a 
versatile endonuclease that plays a role in many genome maintenance pathways (Figure 1-3) 
described in detail later.  
 
 
Figure 1-2: Major domains in XPF and ERCC1 
Schematic representation of XPF and ERCC1 showing the extents in amino acid numbers of the helicase-like 
(black box), the nuclease (red box) and the HhH2-like (dark green box) domains of XPF and the central (orange 
box) and HhH2 (light green box) domains of ERCC1. 
 
All XPF family members in eukaryotes function as heterodimers (Bailly et al., 1992; 
Bardwell et al., 1992; Boddy et al., 2001; Ciccia et al., 2007; Sijbers et al., 1996a). In vertebrates 
there are three types of proteins in the XPF family: those that have nuclease activity (XPF and 
MUS81), one with translocase activity (FANCM), and those that do not have either of these 
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activities, but are binding partners of proteins with these activities (ERCC1, EME1 and 2, and 
FAAP24). Together, they form three endonucleases and one translocase (Figure 1-3). 
The EME1-MUS81 and EME2-MUS81 endonucleases show specificity for flap 
structures and replication forks (Bastin-Shanower et al., 2003; Ciccia et al., 2003; Ciccia et al., 
2007). Their yeast counterparts can also process recombination intermediates, such as D-loops 
and nicked Holliday junctions (Gaillard et al., 2003; Osman et al., 2003). Physiologically, the 
yeast homologs of EME1-MUS81 play a role in meiotic recombination in generating crossover 
products. This role is more pronounced in S. pombe (Osman et al., 2003; Smith et al., 2003) than  
in S. cerevisiae (de los Santos et al., 2003; de los Santos et al., 2001), indicating the presence of 
other redundant pathways. MUS81 deficiency in humans leads to decreased mitotic 
recombination (Blais et al., 2004). The major role of EME1-MUS81 is the resolution of stalled 
replication forks. It is required for formation of a double strand-break (DSB) when a replication 
fork is stalled by an ICL (Hanada et al., 2006). Similarly, yeast homologs are required for repair 
of stalled forks produced by various DNA damaging agents such as camptothecin, 
methylmethanesulfonate, UV irradiation and Hydroxyurea (Bastin-Shanower et al., 2003; Boddy 
et al., 2000; Doe et al., 2002). 
The most recently discovered members of the XPF family are FANCM and FAAP24 
(Ciccia et al., 2007; Meetei et al., 2005). These proteins heterodimerize to form a translocase that 
has an affinity for splayed arm substrates (Ciccia et al., 2007). It lacks helicase or nuclease 
activity and may be involved in loading of the FA core complex on to the chromatin during ICL 
repair (Kim et al., 2008a). 
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Figure 1-3: Orthologs of XPF 
Orthologs of XPF: members of the XPF family in archaea, yeast and vertebrates. Archaea have only one member of the family 
(Hef/XPF). Yeasts S. cerevisiae and S. pombe have 4 members, the homologs of ERCC1 (Rad10/Swi10) and XPF (Rad1/Rad16) and 
homologs of MUS81 (Mus81) and EME1  (Mms4/Eme1). Vertebrates possess three additional members, EME2, which dimerizes with 
MUS81 to form the EME2-MUS81 endonuclease, and FANCM and FAAP24, which participate in the Fanconi anemia pathway. 
Heterodimers formed by these proteins and their functions in vertebrates are listed in the box. 
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1.3 BIOLOGICAL FUNCTIONS OF ERCC1-XPF AND ITS HOMOLOGS 
1.3.1 Nucleotide excision repair 
NER is a DNA repair pathway that repairs a wide variety of helix-distorting lesions affecting one 
strand of DNA. It is a complex pathway involving as many as 30 proteins that perform a highly 
coordinated excision of the damage as a single-stranded oligonucleotide leading to the formation 
of a gap, which is subsequently filled in by replicative polymerases (de Laat et al., 1999; Gillet 
and Scharer, 2006).  
The role of ERCC1-XPF homologs in NER was first identified in S. cerevisiae. RAD1 
and RAD10 mutants were found to be hypersensitive to UV irradiation and defective in the 
incision step of NER (Reynolds et al., 1981; Wilcox and Prakash, 1981). Studies of the S. 
cerevisiae Rad10-Rad1 showed that it was only functional as an endonuclease when it was a 
heterodimer (Davies et al., 1995). It showed specificity for substrates with junctions of ssDNA 
(ssDNA) and double-stranded DNA (dsDNA) with 3’ single-stranded overhangs; releasing the 3’ 
overhangs (Bardwell et al., 1994; Davies et al., 1995). Similarly, ERCC1 and XPF were 
discovered from their roles in NER and the ability of these proteins to restore UV resistance to 
NER-deficient CHO cell lines (Brookman et al., 1996; van Duin et al., 1986). Subsequently, 
ERCC1-XPF was shown to possess structural specificity similar to Rad10-Rad1 in incising 
junctions of single- and double-stranded DNA (de Laat et al., 1998a; Sijbers et al., 1996a). 
NER consists of two pathways, global genome NER (GG-NER) and transcription-
coupled NER (TC-NER) that feed into a common nucleotide excision repair pathway (Hanawalt, 
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2002). As the name suggests, GG-NER deals with DNA damage throughout the genome, 
whereas TC-NER allows the cell to preferentially repair the transcribed strand of genes (Bohr et 
al., 1985; Mellon and Hanawalt, 1989; Mellon et al., 1987). GG-NER is initiated by the 
XPC/hHR23B, which detects helix distortion (Araki et al., 2001; Sugasawa et al., 1998; Volker 
et al., 2001), while TC-NER is initiated when transcription by RNA polII is blocked a DNA 
lesion (Leadon and Lawrence, 1991; Venema et al., 1992). Recognition of damage by either 
initiates a sequential recruitment and assembly of the downstream proteins (Houtsmuller et al., 
1999; Volker et al., 2001). TFIIH, a basal transcription factor is recruited to the site of damage. 
XPG, a structure specific endonuclease, is present in stable association with TFIIH and is 
required for its role in NER as well as transcription (Ito et al., 2007). DNA strands are separated 
into a bubble intermediate by the helicase activity of the TFIIH-component helicases, XPB 
(Schaeffer et al., 1993) and XPD (Schaeffer et al., 1994). This is followed by the recruitment of 
XPA and RPA (Tapias et al., 2004; Wakasugi and Sancar, 1998). In TC-NER, CSA (Henning et 
al., 1995), CSB (Troelstra et al., 1992) and XAB2 (Nakatsu et al., 2000) are also required in 
addition to TFIIH. XPA then recruits ERCC1-XPF through its interaction with ERCC1 (Li et al., 
1994; Li et al., 1995; Park and Sancar, 1994; Saijo et al., 1996). Recruitment of ERCC1-XPF 
allows the release of TFIIH from the bubble (Riedl et al., 2003). The 5’-end of the repair bubble 
produced by the NER machinery is an ideal substrate for incision by ERCC1-XPF (Bardwell et 
al., 1994; de Laat et al., 1998a; Sijbers et al., 1996a). The physical presence of XPG, although 
not its nuclease activity, is required for the 5’ incision by ERCC1-XPF (Mu et al., 1997; 
Wakasugi et al., 1997). On the other hand, the nuclease activity of ERCC1-XPF is required for 
efficient strand cleavage by XPG and the 5’ incision by ERCC1-XPF precedes the 3’ incision by 
XPG (Staresincic et al., 2009). Following the incision, recruitment of RF-C releases ERCC1-
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XPF from the DNA (Mocquet et al., 2008). PCNA, RPA, RF-C and pol δ/ε (Shivji et al., 1995) 
assemble to release XPG (Mocquet et al., 2008) and fill in the gap, and ligase I (Shivji et al., 
1995) or ligase III/XRCC1 seal the nick (Moser et al., 2007). 
1.3.2 Interstrand crosslink repair 
ICLs are formed when a bifunctional alkylating agent covalently binds a base on each strand of 
duplex DNA, thereby preventing strand separation necessary for replication or transcription 
(McHugh et al., 2001). In S-phase cells ICLs are converted into DSBs. This makes crosslinks 
extremely cytotoxic. The ICL repair mechanism in mammals remains poorly defined. Proteins 
from multiple DNA damage repair and tolerance pathways appear to be involved in ICL repair. 
Data from genetic analysis and crosslink hypersensitivity of mutant cells and organisms shows 
the involvement of ERCC1-XPF (Collins, 1993), HR proteins such as XRCC2 and XRCC3 (De 
Silva et al., 2000; Liu et al., 1998), MutSβ (Zhang et al., 2002), RPA, PCNA (Li et al., 2000; 
Zhang et al., 2003), PSO4 complex (PSO4/PRP19, CDC5L, PLRG1, SPF27) (Zhang et al., 
2005), WRN (Zhang et al., 2005), BRCA2 (Yu et al., 2000), EME1-MUS81 (Abraham et al., 
2003; McPherson et al., 2004), SNM1a and SNM1b (Bae et al., 2008; Dronkert et al., 2000; 
Hazrati et al., 2008; Ishiai et al., 2004) and the Fanconi anemia (FA) proteins (Auerbach and 
Wolman, 1976; Fujiwara and Tatsumi, 1977; Sasaki and Tonomura, 1973; Thompson and Hinz, 
2009).  
When the replication machinery encounters a crosslink, because the two strands of DNA 
cannot be separated, it cannot move past the damage, and the replication fork is therefore 
blocked. This activates ATR (Stiff et al., 2006), which along with its downstream target CHK1 
phosphorylates multiple proteins, which include the FA proteins FANCA, FANCG, FANCE, 
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FANCD2, FANCI and FANCM (Andreassen et al., 2004; Collins et al., 2009; Matsuoka et al., 
2007; Meetei et al., 2005; Pichierri and Rosselli, 2004; Qiao et al., 2004; Smogorzewska et al., 
2007; Wang et al., 2007; Yamashita et al., 1998), and H2AX (Ward and Chen, 2001) and NBS1 
(Pichierri and Rosselli, 2004). These phosphorylations activate the FA pathway leading to 
monoubiquitination of FANCD2 and FANCI – the ID complex – that act as a signal for cell 
cycle checkpoints and DNA repair (Meetei et al., 2003; Smogorzewska et al., 2007). This step is 
not dependent on ERCC1-XPF, and FANCD2 monoubiquitination appears to be normal although 
persistent in ERCC1-XPF deficient cells (Bhagwat et al., 2009a). To repair a crosslink it must be 
removed from both strands of DNA, one at a time, and therefore poses a considerable challenge 
to cells. Initial incision is probably made by the ERCC1-XPF ortholog EME1-MUS81, 
producing a DSB (Hanada et al., 2007; Hanada et al., 2006). ICL-induced DSBs can occur even 
in the absence of ERCC1-XPF (Niedernhofer et al., 2004). However, ERCC1-XPF is required 
for the resolution of these breaks. It makes the incision on the other side of the crosslink, thereby 
releasing it from one strand, a process known as “unhooking” (De Silva et al., 2000; Kuraoka et 
al., 2000; Niedernhofer et al., 2004). This function of ERCC1-XPF is necessary for the efficient 
binding of FANCD2 to the chromatin (Bhagwat et al., 2009a; McCabe et al., 2008). Once the 
ICL is unhooked, a translesion polymerase, such as polζ could fill the gap in an error prone 
fashion (Raschle et al., 2008). The FA proteins then coordinate the repair of the replication fork 
through recruitment of the homologous recombination repair (HRR) (Thompson and Hinz, 
2009).  
The ICL repair mechanism in S. cerevisiae is well studied and appears to be different 
from its mammalian counterpart. In this case, unlike ERCC1-XPF in mammals, Rad10-Rad1 
seems to be involved in ICL repair as a part of the NER machinery. In yeast, ICL repair is 
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performed by a combination of NER, HRR (Jachymczyk et al., 1981), PSO2/SNM1 (Henriques 
and Moustacchi, 1980; Henriques et al., 1989; Ruhland et al., 1981), base excision repair 
(McHugh et al., 1999), mismatch repair (Durant et al., 1999) and translesion synthesis (Sarkar et 
al., 2006). 
1.3.3 Double strand break repair 
HRR is a mechanism for repair of DSBs utilizing a homologous DNA sequence. The role of 
ERCC1-XPF in DSB repair was first described in the yeast homolog, Rad10-Rad1. Rad10-Rad1 
was initially described to function in a subtype of HRR, independent of Rad52 (Schiestl and 
Prakash, 1988, 1990) and involves the formation of intrachromosomal heteroduplex 
intermediates between regions containing repeat sequences (Klein, 1988). During the process of 
HRR, the template strand and the invading strand must be completely homologous for the 
stability of the intermediate and for the repair to proceed. Rad10-Rad1 in complex with Msh2 
and Msh3 is required to process 3’ ends that have more than 30 overhanging nucleotides (Paques 
and Haber, 1997). This mechanism of recombination is responsible for gene conversion.  
Similarly, Rad10-Rad1 functions in the error prone DSB repair subtypes: single strand 
annealing (SSA) and microhomology mediated end joining (MMEJ), which can repair DSBs in 
regions of DNA containing sequence repeats. After exonuclease-processing of ends, 3’ 
overhangs are formed on both sides, which may contain non-homologous sequences. Rad10-
Rad1 can prune the ends to remove nonhomologous sequences and allow repair to occur 
(Fishman-Lobell and Haber, 1992; Ivanov and Haber, 1995). SSA is independent of Msh2 and 
Msh3 for regions of homology >1kb (Sugawara et al., 1997), but is dependent on Rad52 
(Mortensen et al., 1996).  
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ERCC1-XPF was found to interact with RAD52 and enhance the ability of the nuclease 
in incising 3’ flaps (Motycka et al., 2004). It was later discovered that ERCC1-XPF has a role in 
SSA and in gene conversions similar to yeast (Al-Minawi et al., 2008). Also, Ercc1 mutant CHO 
cells are deficient in processing heteroduplex intermediates of the recombination between repeat 
sequences (Sargent et al., 2000; Sargent et al., 1997). ERCC1-XPF is required to remove 3’ tails 
that are formed in these intermediates and failure to remove these, leads to deletions at the sites 
of recombination. Irrespective of the sequence homology status, ERCC1-XPF is required for 
integration of exogenous DNA into the genome, for example, the targeted gene replacement in 
mouse ES cells (Niedernhofer et al., 2001). 
MMEJ is independent of Rad52 and Ku86, but requires Mre11-Rad50-Xrs2 (the MRX 
complex) (Haber, 2006), Msh2, Pms1 (Decottignies, 2007), Nej1, multiple DNA polymerases 
including Pol4, Rad30, Rev3, and Pol32, the flap endonuclease Sae2, and Tel1 (Lee and Lee, 
2007). In mammals, the existence of the MMEJ pathway is evident from persistent end joining 
repair in non-homologous end joining (NHEJ) deficient cells (Kabotyanski et al., 1998). Ercc1-/-
Ku86-/- mice are not viable and the double knockout MEFs are more sensitive to radiation than 
the single mutants. However, Ercc1-/- mouse ES cells are not hypersensitive to radiation, 
suggesting that this is not a defect of HRR. Linearized plasmid DNA with microhomologies on 
both ends, which are substrates for MMEJ, shows large deletions after repair in Ercc1 mutant 
CHO cells. Overall, these data suggest that ERCC1-XPF functions in a Ku-independent error 
prone pathway of end joining (Ahmad et al., 2008). 
In S. pombe, individual cells undergo spontaneous mating-type switch during growth. 
This involves formation of a DSB at a switching signal locus followed by recombination-
mediated repair. Strains rad16 (swi9) and swi10 have a defect in the mating-type switching 
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recombination mechanism (Carr et al., 1994; Schmidt et al., 1989). Additionally, they are also 
sensitive to ionizing radiation (Schmidt et al., 1989). In A. thaliana, deficiency of AtERCC1 led 
to radiation sensitivity, indicating a role in DSB repair (Hefner et al., 2003). In Drosophila, 
mutation of mei-9 also leads to radiation sensitivity (Baker et al., 1978). Thus, ERCC1-XPF and 
its homologs function in multiple subtypes of DSB repair. 
1.3.4 Meiotic recombination 
Meiosis is accompanied by crossover events between homologous chromosomes, allowing for 
segregation of polymorphisms. This crossover is brought about by meiotic recombination, a 
mechanism akin to the HRR mechanism, but between homologous chromosomes with divergent 
sequences, instead of sister chromatids that are identical at the sequence level. Drosophila mei-9 
mutants are defective in meiotic crossover. They display a marked decrease in crossovers and an 
increase in chromosome non-disjunctions (Carpenter and Baker, 1982; Yildiz et al., 2004). There 
is also an increase in postmeiotic segregation, indicating a failure to repair heteroduplex DNA 
formed during noncrossover recombination events (Yildiz et al., 2004). These findings suggest 
that MEI-9 is required for the resolution of Holliday junctions (HJ) formed during meiosis. MEI-
9 interacts with MUS312, and disruption of MUS312-MEI-9 interaction produces a phenotype 
similar to the loss of either MUS312 or MEI-9 (Yildiz et al., 2002). Recent evidence suggests 
that HDM, a single-stranded-DNA binding protein forms a complex with MUS312, MEI-9 and 
ERCC1 that resolves the HJs (Joyce et al., 2009). Interestingly, the human ortholog of MUS312, 
BTBD12 (SLX4) binds multiple different endonucleases including ERCC1-XPF (Fekairi et al., 
2009; Svendsen et al., 2009). 
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Mice have elevated Xpf and Ercc1 mRNA levels in the meiotic and early postmeiotic 
cells involved in spermatogenesis (Shannon et al., 1999). Both male and female Ercc1-mutant 
mice are infertile. ERCC1-XPF is important at all stages of development and maturation of both 
male and female gametes, but there is no evidence that it is required for meiotic crossovers (Hsia 
et al., 2003). 
1.3.5 Telomere maintenance 
Telomeres have 3’ overhangs with G-rich repeat sequences. This is an ideal substrate for 
cleavage by ERCC1-XPF. ERCC1-XPF was found to be associated with the telomeric TRF2 
complex, and prevents recombination of telomeric DNA with interstitial telomere-like repeats. 
The absence of ERCC1-XPF produces telomeric DNA-containing double minute (TDM) 
chromosomes. On the other hand, in the absence of TRF2, ERCC1-XPF cleaves the 3’ overhangs 
allowing telomeres to be subjected to NHEJ. This leads to telomere fusions and dicentric 
chromosomes (Zhu et al., 2003). In essence, ERCC1-XPF and TRF2 seem to be acting 
antagonistically, preventing each other from damaging the telomere. Strangely, TRF2-dependent 
loss of telomeres, caused by TRF2 overexpression is dependent on ERCC1-XPF (Munoz et al., 
2005). What is even more perplexing is that this action requires the physical presence of ERCC1-
XPF, but not its nuclease activity (Wu et al., 2007). Also, overexpression of wild-type but not 
nuclease-dead XPF reduces the telomere binding of TRF2. Apparently, ERCC1-XPF acts on the 
telomere through two distinct mechanisms, a nuclease-dependent mechanism that affects TRF2 
binding, and a nuclease-independent mechanism that limits telomere length (Wu et al., 2008). 
ERCC1-XPF interacts with TRF1 in a very similar way and contributes to telomere shortening 
and end-fusions in the absence of TRF1 (Munoz et al., 2009). A similar mechanism exists in A. 
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thaliana, where ERCC1-XPF prevents recombination of telomeres with interstitial telomeric 
repeats (Vannier et al., 2009). 
1.3.6 Repair of TopI lesions 
Progression of replication forks along DNA creates superhelical strain on the unreplicated 
duplex. Topoisomerase I releases this supercoiling by transiently cutting one strand of the duplex 
and forming a protein-DNA complex with that strand, allowing it to unwind in an ATP 
dependent mechanism (Champoux, 2001). When a replication fork collides with a Top1-DNA 
intermediate, it is blocked, leading to a DSB (Hsiang et al., 1989). Top1 poisons such as 
camptothecin cause the Top1 protein to remain attached to the 3’ end of the unreplicated DNA 
rendering it inaccessible to repair. Tdp1 removes the Top1 molecule and creates a 3’ phosphate 
(Pouliot et al., 1999). In S. cerevisiae this substrate is further processed by the activities of Tpp1, 
Apn1 and Apn2 to convert it from a repair-blocking lesion to a 3’ hydroxyl group amenable to 
repair (Vance and Wilson, 2001). Although the yeast RAD1 and RAD10 mutants are not sensitive 
to Top1 poisons such as camptothecin, Rad10-Rad1 was found to function in a backup pathway 
for repair of Top1 lesions (Liu et al., 2002; Vance and Wilson, 2002). In the absence of Tdp1, 
Rad10-Rad1 likely incises a 3’ single stranded flap, removing an oligonucleotide containing the 
Top1-DNA intermediate and allowing for a Rad52-dependent homologous recombination to 
repair the fork (Vance and Wilson, 2002). 
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1.3.7 Repair of abasic sites 
Apurinic/apyrimidinic (AP) sites are produced as a result of depurination or depyrimidination of 
DNA due to spontaneous hydrolysis of the bond between the base and the DNA backbone. In a 
mammalian cell, over a span of 24 hours approximately 10,000 purines (Lindahl, 1979) and 
about 500 pyrimidines (Lindahl and Karlstrom, 1973) are lost by this process. AP sites are also 
produced by DNA glycosylases as intermediates of base excision repair (BER) (Duncan et al., 
1976; Lindahl, 1976). In S. cerevisiae removal of misincorporated uracil by uracil DNA 
glycosylase appears to be the major endogenous contributor towards AP sites (Guillet and 
Boiteux, 2003). S. cerevisiae mutants defective in both yeast AP endonucleases are viable, but 
triple mutants apn1 apn2 rad1 and apn1 apn2 rad10 are not viable, suggesting that Rad10-Rad1 
functions in a backup pathway of AP site repair (Guillet and Boiteux, 2002). Although NER 
plays a role in removal of AP sites (Swanson et al., 1999; Torres-Ramos et al., 2000) this 
mechanism seems to be independent of NER, as evident from the viability of apn1 apn2 rad14 
strains (Guillet and Boiteux, 2002). In this case, the genetic evidence suggests that similar to the 
Top1 lesion repair, Rad10-Rad1 works by removing the 3’ flap resulting from the spontaneous 
hydrolysis of the abasic site (Boiteux and Guillet, 2004). 
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1.4 PHYSIOLOGICAL FUNCTIONS OF ERCC1-XPF 
1.4.1 Human diseases associated with defects in ERCC1-XPF 
The severity and manifestation of ERCC1-XPF deficiency in humans varies significantly. 
Interpretation of the phenotype is complicated by the involvement of ERCC1-XPF in multiple 
genome maintenance mechanisms. 
1.4.1.1 Xeroderma pigmentosum 
Xeroderma pigmentosum (XP) was the first hereditary condition to be associated with defect in a 
DNA repair pathway. It is an autosomal recessive syndrome characterized by sun sensitivity with 
a 2000-fold increase in skin cancers over sun-exposed areas, which include basal cell carcinoma, 
squamous cell carcinoma, malignant melanoma, keratoacanthoma, fibrosarcoma, and angioma 
(Kraemer et al., 1987). There is also evidence for increased incidence of sarcomas. Patients with 
mutations affecting both global and transcription-coupled NER present with progressive 
neurodegeneration, probably due to accumulation of damage in transcribed genes (Brooks, 
2008). The severity and age of presentation varies widely amongst patients, depending on the 
mutation and the protein affected. XP has eight complementation groups from XP-A through G 
and the variant form, XP-V. XP-F was first reported in Japan and usually presents with a mild 
phenotype with late onset of disease (Matsumura et al., 1998), although in some cases a late 
onset neurodegenerative phenotype is seen. Mutant XPF protein may fail to localize to the 
nucleus, leading to mislocalization of both ERCC1 and XPF to the cytoplasm. This produces a 
phenotype disproportionate to the ability of these mutants to reconstitute NER in vitro (Ahmad et 
al, submitted manuscript). There is no known ERCC1 mutation that presents as XP. 
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1.4.1.2 XFE progeroid syndrome 
Most patients with XPF mutations have a mild XP phenotype. However, a patient with XPF 
R153P mutation presented with a progeroid phenotype in addition to sun sensitivity 
(Niedernhofer et al., 2006). Arginine-153 lies in the helicase-like domain of XPF and is highly 
conserved. To date this remains the only published case of the XFE (XPF-ERCC1) progeroid 
syndrome. Remarkably, despite photosensitivity and abnormal skin pigmentation, there was no 
evidence of skin cancer. There was evidence of growth retardation, including short stature, 
microcephaly and developmental delay. Further investigations showed an array of aging-related 
degenerative changes. Although the patient had a normal birth-weight, he was cachexic at 
presentation. His skin was dry and atrophic, and lacked subcutaneous fat. He had bird-like facies 
with prominent bones and an aged appearance. Neurodegeneration was evident from cerebral 
atrophy, tremors and ataxia with loss of coordination, impaired hearing and vision loss with optic 
atrophy. Scoliosis, muscle wasting and hypotonia suggested musculoskeletal degeneration. In 
addition, there was hypertension, renal and hepatic insufficiency, and anemia, which 
distinguished this case from the DeSanctis-Cacchione and Cockayne syndromes. The patient 
died at the age of 16 years from multi-organ failure following pneumonia. These symptoms are 
remarkably similar to the presentation of the Ercc1-/- (Niedernhofer et al., 2006) and the Xpf m/m 
(Tian et al., 2004) mouse models which also show an accelerated aging phenotype. 
Fibroblasts obtained from skin biopsy of the patient showed markedly decreased UV 
induced unscheduled DNA synthesis (UV-UDS) (~5% of wild-type). They were more sensitive 
to UV than XP-F patient fibroblasts, though less so than XP-A fibroblasts. They were exquisitely 
hypersensitive to the crosslinking agent MMC, indicating that a deficiency in ICL repair may 
have a significant contribution to this phenotype. 
  20 
1.4.1.3 Cranio-occulo-facio-skeletal syndrome (COFS) 
The only known patient of ERCC1 mutation was born with low birth-weight, microcephaly with 
premature closure of the fontanels, bilateral microphthalmia, blepharophimosis, high nasal 
bridge, short filtrum, micrognathia, low-set and posterior-rotated ears, arthrogryposis with 
rocker-bottom feet, flexion contractures of the hands, and bilateral congenital hip dislocation. 
MRI showed a simplified gyral pattern and cerebellar hypoplasia. This was diagnosed as COFS. 
The classic COFS is defined by microcephaly, hypotonia, microphthalmia, cataracts, 
blepharophimosis, large ear pinnae, prominent root of the nose, micrognathia, wide set nipples, 
camptodactyly, flexure contractures at the elbows and knees, generalized osteoporosis, dysplastic 
acetabula, coxa valga, rocker-bottom feet and failure to thrive (Pena and Shokeir, 1974). 
Previously, COFS has been diagnosed in patients with mutations of either CSB (Meira et al., 
2000) or XPD (Graham et al., 2001).  
The cerebellar hypoplasia seen in this patient was also seen in Ercc1-/- mice at the age of 
1 day. This was alleviated almost completely by the age of 4 days, suggesting that this was in 
fact a defect in neuronal migration. This is analogous to the Xpa and Csb double knockout mouse 
model, which shows a reduced cerebellar foliation and stunted Purkinje cell dendrites (Murai et 
al., 2001). The child failed to thrive and did not pas any developmental milestones, dying at the 
age of 14 months (Jaspers et al., 2007). The phenotype of growth retardation, neurological deficit 
and shortened lifespan matches with the phenotype of Ercc1-/- mice. Together, these observations 
show that ERCC1 is essential for human development and viability. 
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1.4.2 Mouse models of ERCC1-XPF deficiency 
1.4.2.1 Ercc1-/- mouse 
Two groups independently made Ercc1-/- mice (McWhir et al., 1993; Weeda et al., 1997). In the 
first case, Ercc1 was targeted with a neo insert between exons 4 and 6 using an HPRT minigene 
based system (Selfridge et al., 1992). In the second case, two mouse models were made, one 
with a neo insert in exon 7 (Ercc1-knockout mouse) and the other with a stop codon at position 
292 of ERCC1, producing a truncated version of the transcript (Ercc1*292 or Ercc17Δ allele, 
discussed further under Ercc1 hypomorphs). The Ercc1-knockout mice are born at sub-
Mendelian ratios due to an early embryonic lethality. All mutant mice are runted at birth and 
display shortened lifespan of about 3 - 4 weeks. The mutant mice show abnormalities of liver, 
with large polyploid nuclei. Mice die of hepatic failure and show increased p53 in liver, kidneys 
and brain (McWhir et al., 1993). The primary MEFs isolated from these mice grow slower than 
their wild-type counterparts (Niedernhofer et al., 2006; Weeda et al., 1997). These MEFs and 
mouse livers have elevated p21 levels, suggesting that they are undergoing senescent changes 
(Nunez et al., 2000; Weeda et al., 1997). Also, as noted before, the Ercc1-/- mice have delayed 
cerebellar development (Jaspers et al., 2007). This phenotype is dramatically different from that 
of Xpa-/- mice, which are phenotypically nearly indistinguishable from the wild-type littermates 
(de Vries et al., 1995). Ercc1-/- mice have reduced hematopoietic reserve and demonstrate a 
multilineage cytopenia with reduction in stress induced erythropoiesis and fatty replacement of 
the bone marrow (Prasher et al., 2005). This resembles Fanconi anemia, a disease characterized 
by hypersensitivity to ICL repair (Parmar et al., 2009). This suggests that at least a part of the 
phenotype of Ercc1-/- mice is due to a deficiency in ICL repair. Additionally, these mice show 
neurodegenerative changes including dystonia and ataxia, musculoskeletal degeneration evident 
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from sarcopenia and kyphosis and renal failure. Combined with the cellular senescence these 
findings suggest accelerated aging and led to the identification of anew humn progeria cased by 
the reduced expression of ERCC1-XPF (Niedernhofer et al., 2006). 
1.4.2.2 Xpf m/m mouse 
Mouse Xpf was mutated with a neo insert between exons 7 and 8 and a stop codon at position 
445 (Tian et al., 2004). In keeping with the obligate heterodimeric nature of ERCC1 and XPF, 
the mouse is a phenocopy of the Ercc1-/- mouse. The mice are runted, with enlarged and 
polyploid hepatocytes and die within 3 weeks of birth. Further analysis was not done. 
1.4.2.3 Ercc1 hypomorphs 
The Ercc1∆/∆ mice were generated by inserting a stop codon at position 292 of Ercc1 (Weeda et 
al., 1997). This resulted in a truncated transcript and presumably a protein that is seven amino 
acids short at the C-terminus. The C-terminus of ERCC1 is indispensible for its function (Sijbers 
et al., 1996b) and so the truncation should significantly affect the function of ERCC1-XPF. In 
fact, the transcript from the ∆  allele is reduced to about 15% of the wild-type allele (Weeda et 
al., 1997). The Ercc1∆/∆ mice live for about 6 months from birth, a lifespan intermediate between 
the Ercc1-/- and wild-type mice. Aside from liver changes reminiscent of the knockout mice, they 
also display ferritin deposition in the spleens, thin skin lacking subcutaneous fat and renal 
tubular dilatation with abnormal nuclei and proteinuria indicative of renal insufficiency. Unlike 
the Ercc1-/- mice, TUNEL assay shows no evidence of increased apoptosis in tissues. The mice 
are infertile, but histologically both ovaries and testes appear normal. Ercc1-/∆ mice with LacZ 
transgene were analyzed by recovery of LacZ containing plasmid and isolating clones lacking 
LacZ expression. LacZ mutants were further analyzed to determine the type of mutations leading 
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to inactivation of the gene. This LacZ mutation analysis shows a rapid accumulation of 
mutations in the livers of these animals. Mutations included point mutations similar to the NER 
deficient Xpa-/- mice and deletions and translocations, probably stemming from the loss of ICL 
repair and DSB repair related functions of ERCC1-XPF (Dolle et al., 2006). 
1.4.2.4 Ercc1 conditional mutants 
In order to correct the hepatic failure of Ercc1-/- mice, transgenic Ercc1 was expressed with a 
liver specific transthyretin promoter (Selfridge et al., 2001). This prevented the polyploidy of 
hepatocytes and liver failure, and increased lifespan up to 61 – 88 days, but the mice died of 
renal failure with a similar polyploid phenotype in the proximal tubule cells. These mice also had 
elevated plasma lactate levels, pointing towards possible mitochondrial consequences of ERCC1 
deficiency. Neurodegeneration was evident from lack of coordination, ataxia and loss of visual 
acuity, but no histological changes in the brain were detected (Lawrence et al., 2008). 
Ercc1-/- mice have an extremely short lifespan, making it difficult to study the UV 
sensitivity of their skin. To overcome this problem, mice were made with a floxed Ercc1 allele 
under bovine K5 promoter. These mice showed 20-fold increase in sensitivity to the short-term 
erythematous changes in epidermis with UV-B irradiation. They also displayed a rapid onset of 
tumors, mainly squamous cell carcinomas, which grew faster than those in wild-type animals 
(Doig et al., 2006). 
1.4.3 Altered expression of ERCC1-XPF in cancers 
ERCC1-XPF functions in major genome maintenance pathways including NER (Sijbers et al., 
1996a), ICL repair (De Silva et al., 2000), DSB repair (Murray et al., 1996; Murray and 
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Rosenberg, 1996) and telomere maintenance (Wu et al., 2008; Zhu et al., 2003). Various 
chemotherapeutic agents and radiotherapy kill cancer cells by damaging their DNA. If ERCC1-
XPF expression is variable in cancers, it may have a bearing on the growth characteristics of 
tumors, their response to various therapies and patient survival. This promise has led to extensive 
attempts at devising strategies to evaluate the effect of both ERCC1 and XPF, but mainly 
ERCC1, on tumor biology. These include studies of short nucleotide polymorphisms (SNP), 
mRNA levels, and Immunohistochemistry for protein levels.  
1.4.3.1 SNPs 
SNPs may affect protein expression or function based on their nature and location. A non-
conservative base substitution may change amino acid sequence, thereby directly affecting 
protein function. A conservative substitution may alter rate of mRNA translation by altering the 
choice of tRNA or effect on protein folding due to slow translation. Polymorphisms near 
promoters or introns can affect protein expression through transcription. There is however no 
direct evidence that polymorphisms of ERCC1 or XPF can affect protein levels. A survey of 
polymorphisms in NER genes found that ERCC1 contains at least seven SNPs that do not alter 
amino acid sequence; XPF has six. ERCC1 contains no SNPs with amino acid substitutions, 
while XPF has one that leads to P379S substitution (Shen et al., 1998). A commonly studied 
silent polymorphism of ERCC1, codon 118(C/T) changes a commonly used codon AAC to 
AAT, one that is used infrequently. This can potentially reduce the translation of the mRNA 
leading to reduced protein levels (Yu et al., 1997). Once again, there is no evidence of a 
difference in protein or mRNA levels caused by this SNP. Despite this, ERCC1 SNPs have 
shown correlation with outcomes of many different types of tumors. Of these, non-small cell 
lung carcinoma (NSCLC) has been the most extensively studied. Numerous studies have found 
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correlation between risk, survival and treatment response in NSCLC with either or both of codon 
118 and C8092A polymorphisms of ERCC1 (Isla et al., 2004; Kalikaki et al., 2009; Park et al., 
2006; Su et al., 2007; Takenaka et al., 2009; Zienolddiny et al., 2006). On the other hand, a large 
meta-analysis of multiple studies failed to find any correlation (Kiyohara and Yoshimasu, 2007). 
Several other cancers, including esophageal cancer (Doecke et al., 2008; Pan et al., 2009), 
ovarian cancer (Steffensen et al., 2008), squamous cell carcinoma of head and neck (Quintela-
Fandino et al., 2006), basal cell carcinoma (Yin et al., 2003) and bladder cancer (Garcia-Closas 
et al., 2006) have shown correlation of outcome or chemotherapy resistance to ERCC1 
genotypes. However, studies involving pancreatic adenocarcinoma (McWilliams et al., 2008), 
carcinoma of prostate (Hooker et al., 2008), colorectal carcinoma (Hansen et al., 2008; Monzo et 
al., 2007), glioma (Chen et al., 2007), renal cell carcinoma (Hirata et al., 2006) and cervical 
carcinoma (Chung et al., 2006) did not find any link to ERCC1 SNPs. 
1.4.3.2 mRNA 
Interest in ERCC1 mRNA levels stemmed from the thought that these may be representative of 
the functional ERCC1 in cells. There is no evidence to suggest that ERCC1 is regulated at the 
level of transcription. In fact, mRNA levels of ERCC1 and XPF have absolutely no correlation to 
their respective protein levels (Niedernhofer et al., unpublished data). All the same, multiple 
studies have suggested a correlation between the level of ERCC1 mRNA in tumors or tumor cell 
lines from gastric, ovarian, colorectal, esophageal and non-small cell lung cancer and resistance 
to cisplatin (Altaha et al., 2004; Dabholkar et al., 1992; Dabholkar et al., 1994; Joshi et al., 
2005; Langer et al., 2005; Lord et al., 2002; Metzger et al., 1998; Reed et al., 2000; Rosell et al., 
2002; Shirota et al., 2001; Warnecke-Eberz et al., 2004). Similar to SNPs, mRNA levels of 
ERCC1 are the most extensively studied in NSCLC. Based on findings that patients with low 
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ERCC1 expression in tumors respond better to cisplatin-based therapy (Lord et al., 2002), a 
clinical trial was carried out. Patients who received tailored chemotherapy based on the ERCC1 
expression performed better than those who received a standard control therapy with docetaxel 
and cisplatin (Cobo et al., 2007). Patients with low ERCC1 levels performed somewhat better 
than those with high ERCC1 levels. 
1.4.3.3 Protein levels in tumors 
Measurement of ERCC1 levels by IHC of paraffin-embedded tumor samples is an attractive 
biomarker to study the effect of ERCC1 levels on tumor response to various chemotherapeutic 
agents and patient survival. This is due to the relative ease of availability of samples, relative 
stability of proteins over RNA and advantage of processing large sets of samples economically 
over a short period of time. NSCLC remains the most studied tumor type (Hwang et al., 2008; 
Lee et al., 2008; Olaussen et al., 2006; Zheng et al., 2007). However, there are mixed results as 
to whether ERCC1 levels are predictive of resistance depending on the type of therapy 
administered. High ERCC1 expression correlated with poor response to cisplatin chemotherapy 
and poor survival outcome (Olaussen et al., 2006). On the other hand high ERCC1 was 
associated with better survival following surgery (Lee et al., 2008; Zheng et al., 2007). 
Unfortunately, the antibody (8F1) used in almost all studies is not specific for ERCC1 
(Niedernhofer et al., 2007). It recognizes human ERCC1, but also a second unknown nuclear 
antigen, and is unable to discriminate between cells expressing ERCC1-XPF and cells that do not 
(Niedernhofer et al., 2007). We rigorously tested antibodies against ERCC1 and XPF and found 
ones that are best suited for clinical measurement of ERCC1-XPF (Bhagwat et al., 2009b). Our 
results show that ERCC1 and XPF levels in lung tumors vary considerably between tumors, but 
are closely correlated to each other and either of these proteins can be used as a surrogate 
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biomarker. More study however, remains to be performed to fully evaluate the utility of ERCC1 
and XPF as cancer biomarkers. 
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2.0  XPF-ERCC1 PARTICIPATES IN THE FANCONI ANEMIA PATHWAY OF 
CROSSLINK REPAIR 
This chapter was accepted for publication as a research article in Molecular and Cellular 
Biology: 
Bhagwat, N., Olsen, A.L., Wang, A.T., Hanada, K., Stuckert, P., Kanaar, R., D'Andrea, 
A., Niedernhofer, L.J., and McHugh, P.J. (2009a). XPF-ERCC1 participates in the Fanconi 
anemia pathway of crosslink repair. Mol Cell Biol, MCB.00086-00009 
Copyright © American Society for Microbiology, Molecular and Cellular Biology, doi: 
10.1128/MCB.00086-09 
2.1 INTRODUCTION 
The XPF-ERCC1 heterodimer is a structure-specific endonuclease that incises double-strand 
DNA immediately adjacent to a 3’-single-stranded region, removing 3’-overhangs or opening 
bubbles (de Laat et al., 1998a; Sijbers et al., 1996a). ERCC1 is required for DNA binding 
(Tsodikov et al., 2005) and XPF harbors the catalytic domain (Enzlin and Scharer, 2002). XPF-
ERCC1 makes the incision 5’ to the lesion during nucleotide excision repair (NER), the pathway 
responsible for removing helix-distorting DNA lesions (Sijbers et al., 1996a). Defects in NER 
cause xeroderma pigmentosum (XP), a syndrome characterised by photosensitivity and 
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dramatically increased risk of skin cancers, due to failure to repair UV-photolesions. Cells from 
all XP complementation groups (XP-A to -G) and the recently reported ERCC1-deficient patient 
(Jaspers et al., 2007) are hypersensitive to UV irradiation. However, cells deficient in XPF-
ERCC1 differ from other XP cells in that they are also exquisitely sensitive to chemicals that 
induce DNA interstrand crosslinks (ICLs) (De Silva et al., 2000; Hoy et al., 1985; Niedernhofer 
et al., 2006) ICLs are extremely cytotoxic lesions formed when bifunctional agents covalently 
link both strands of DNA, preventing strand separation, which is necessary for replication or 
transcription (McHugh et al., 2001). Crosslinking agents such as nitrogen mustards (HN2) (Kohn 
et al., 1966) and mitomycin C (MMC) (Iyer and Szybalski, 1963) produce a mixture of 
monoadducts and ICLs. However, cytotoxicity correlates with the number of ICLs formed, rather 
than monoadducts (O'Connor and Kohn, 1990; Palom et al., 2002). 
ICLs present a unique challenge to cells in that they affect both strands of DNA 
and therefore cannot be repaired by a simple excision and re-synthesis mechanism. The 
mechanism of ICL repair in E. coli is well characterized. It involves the NER complex UvrABC, 
the recombination repair machinery or DNA polymerase II-dependent translesion synthesis 
(Berardini et al., 1999; Cheng et al., 1991; Cole, 1973; Van Houten et al., 1986). In S. 
cerevisiae, ICL repair requires both the NER and the homologous recombination (HR) 
machinery (Jachymczyk et al., 1981). There is also evidence for the involvement of PSO2/SNM1 
(Henriques and Moustacchi, 1980; Henriques et al., 1989; Ruhland et al., 1981), as well as base 
excision repair (McHugh et al., 1999), mismatch repair (Durant et al., 1999) and translesion 
polymerases (Sarkar et al., 2006). ICL repair in mammalian cells, however, remains poorly 
understood. Genetic evidence implicates XPF-ERCC1 (Collins, 1993), HR proteins such as 
XRCC2 and XRCC3 (De Silva et al., 2000; Liu et al., 1998), MutSβ (Zhang et al., 2002), RPA, 
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PCNA (Li et al., 2000; Zhang et al., 2003), PSO4 complex (PSO4/PRP19, CDC5L, PLRG1, 
SPF27) (Zhang et al., 2005), WRN (Zhang et al., 2005) , BRCA2 (Yu et al., 2000), MUS81-
EME1 (Abraham et al., 2003; McPherson et al., 2004), SNM1a and SNM1b (Bae et al., 2008; 
Dronkert et al., 2000; Hazrati et al., 2008; Ishiai et al., 2004) and the Fanconi anemia proteins 
(Auerbach and Wolman, 1976; Fujiwara and Tatsumi, 1977; Sasaki and Tonomura, 1973; 
Thompson and Hinz, 2009). Of these, the Fanconi anemia family of proteins are unique in that 
they appear to be conserved only in higher eukaryotes (D'Andrea and Grompe, 2003; Joenje and 
Patel, 2001). 
Fanconi anemia (FA) is a rare and clinically heterogeneous disease characterised by 
congenital skeletal abnormalities, growth retardation, bone marrow failure, aplastic anemia, 
genomic instability and susceptibility to cancer (D'Andrea and Grompe, 2003; Joenje and Patel, 
2001). The patients have been grouped into 13 distinct complementation groups (FANC-A, -B, -
C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, and -N) each representing deficiency of one protein in the 
Fanconi anaemia pathway. Of these, FANCA, B, C, E, F, G, L, M, and FAAP100 and FAAP24 - 
newly discovered components without complementation groups - form the FA core complex 
(Ciccia et al., 2007; Garcia-Higuera et al., 1999; Ling et al., 2007; Medhurst et al., 2001; Meetei 
et al., 2003; Meetei et al., 2004; Meetei et al., 2005). FANCL is an E3 ubiquitin ligase that 
monoubiquitinates FANCD2 in response to genotoxic stress (Meetei et al., 2003) during S phase 
of the cell cycle (Taniguchi et al., 2002). FANCI – a newly discovered paralog of FANCD2, 
which is also monoubiquitinated – forms a chromatin bound complex with FANCD2. 
Monoubiquitination of both proteins is required for complex stability and ICL repair 
(Smogorzewska et al., 2007). FANCD2 monoubiquitination is commonly used as a read-out to 
define which FA proteins act ‘upstream’ and therefore participate in damage signalling or 
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‘downstream’ and therefore are more likely to directly contribute to ICL repair. 
Monoubiquitinated FANCD2 co-localizes with proteins involved in HR including RAD51 and 
BRCA1 (Digweed et al., 2002; Garcia-Higuera et al., 2001; Taniguchi et al., 2002). FANCD1 is 
identical to BRCA2 (Howlett et al., 2002) and interacts with XRCC3 along with FANCG 
(Hussain et al., 2006), as well as RAD51 (Marmorstein et al., 1998). These data indicate a direct 
physical interaction between the FA proteins and the HR machinery (Wilson et al., 2008). 
The emerging model for the mechanism of ICL repair in mammals suggests that the FA 
pathway is activated in response to ICL damage in an ATR-dependent manner (Andreassen et 
al., 2004; Pichierri and Rosselli, 2004). ATR is activated by blocked replication forks (Stiff et 
al., 2006) and also phosphorylates numerous downstream effectors including FA proteins 
(Andreassen et al., 2004; Meetei et al., 2005; Pichierri and Rosselli, 2004) and H2AX (Ward and 
Chen, 2001). Before a replication fork that is blocked by an ICL can be restarted, the ICL must 
be completely unhooked from one strand of DNA, requiring two incisions 5’ and 3’ of the lesion 
and potentially producing a DSB at the fork. MUS81-EME1 is thought to be responsible for the 
first incision, creating a DSB (Hanada et al., 2007; Hanada et al., 2006). The second incision, or 
unhooking of the crosslink, has been proposed to be a key function of XPF-ERCC1 in ICL repair 
(Niedernhofer et al., 2004). Once the ICL is completely unhooked from one strand, translesion 
synthesis can fill the gap, albeit in an error-prone fashion. The repaired strand can now act as a 
template for re-establishing the replication fork via HR (Niedernhofer et al., 2005).  
To further elucidate the mechanism of ICL repair in mammals, it is necessary to define 
the relationship between the nucleolytic cleavage of crosslinked DNA and the FA pathway. 
Herein we provide evidence that XPF-ERCC1 nuclease participates in the same ICL repair 
mechanism as the FA proteins and that nucleolytic processing of damaged DNA is not required 
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for FA pathway activation, but is required for stable localization of monoubiquitinated FANCD2 
on chromatin. 
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2.2 MATERIAL AND METHODS 
2.2.1 Cell culture and drug treatment 
Human fibroblast lines immortalized by stable expression of human telomerase, C5RO (normal), 
XP51RO (XFE), XP42RO (XP-F), and XP25RO (XP-A) (Niedernhofer et al., 2006) were 
cultured in Ham’s F-10 with 10% fetal bovine serum, antibiotics and non-essential amino acids. 
Cells were treated for 12 hrs with 0.3 µM MMC or for 1 hr with 3 µM MMC diluted in media. 
At the end of the treatment, cells were washed twice with PBS, the media was replaced and the 
cells incubated at 5% CO2 at 37°C under humidity. Time points were calculated with this as 0 hr. 
Wild-type and Ercc1-/- mouse embryonic fibroblasts (MEFs), transformed with SV40 large-T 
antigen, were cultured in 1:1 mixture of Ham’s F-10 and DMEM with 10% fetal bovine serum, 
antibiotics and non-essential amino acids. Wild type, Ercc1-/- (Niedernhofer et al., 2001) and 
Mus81-/- (Hanada et al., 2006) mouse embryonic stem (ES) cells were cultured on gelatin-coated 
plates in a 1:1 mixture of DMEM and Buffalo Rat Liver (BRL) cell conditioned media with 10% 
FBS, antibiotics, non-essential amino acids, 0.1 mM 2-mercaptoethanol and leukemic inhibitory 
factor (1000 U/ml, Gibco). Wild-type (AA8), UV47 (Xpf mutant), UV96 (Ercc1 mutant) and 
UV135 (Xpg mutant) CHO cells were grown as a monolayer in F12-Ham Hepes medium 
(Sigma) supplemented with 5 mM glutamine and 10% fetal calf serum. Cells were grown at 
37°C in a 5% CO2 humidified incubator.  Cells were treated with 1 µM mitomycin C for 12 hrs, 
or for 1 hr with the stated doses of nitrogen mustard (mechlorethamine hydrochloride, Aldrich) 
dissolved in culture medium (without FCS) immediately prior to use. Following nitrogen 
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mustard or mitomycin C treatment, media were removed, cells washed twice with PBS and 
returned to the incubator in drug-free complete media for the stated times. 
2.2.2 Immunoblotting 
Cells were trypsinized, washed with PBS and lysed with 1 ml NETT buffer (100 mM NaCl, 50 
mM Tris base pH 7.5, 5 mM EDTA pH 8.0, 0.5% Triton X-100) containing Complete™ mini 
protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche Molecular Biochemicals). 
From each sample, 50 µg protein was resolved on 6% SDS-PAGE gels. FANCD2 was detected 
with rabbit anti-FANCD2 (for human cells, 1:10000, Novus Biologicals), rabbit anti-murine 
FANCD2 (for mouse cells, 1:1000) or rabbit anti-FANCD2 (for CHO cells, 1:1000, Abcam). 
The loading control used for whole cell extracts (WCEs) was tubulin (rabbit anti-tubulin, 1:1000 
or 1:15,000, Abcam and Sigma, respectively). The loading control for cytoplasmic protein from 
HeLa cells was GRB2 (anti-GRB2, 1:5000, BD Biosciences). The loading control for chromatin 
and nuclear fractions of ES cells was TATA binding protein (mouse anti-TBP, 1:500, Abcam) 
and for hamster cells was ORC2 (mouse anti-ORC2 BD-Pharmingen, 1:800). The loading 
controls for human fibroblasts and MEFs were: nucleophosmin (mouse anti-nucleophosmin, 
1:5000, Millipore) for the soluble nuclear fraction, and Histone H3 (rabbit anti-H3, 1:20,000, 
Abcam) for the chromatin fraction. Secondary antibodies used were: mouse AP (1:7500, 
Promega), rabbit AP (1:1000, Promega), rat HRP (1:5000, Abcam), Rabbit HRP (1:1200, Dako) 
and mouse HRP (1:1500 or 1:2500, Promega). 
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2.2.3 Depletion of ERCC1 by siRNA 
HeLa cells were obtained from Cancer Research UK Clare Hall Cell Services and maintained in 
RPMI supplemented with 10% fetal calf serum and glutamine without antibiotics. Cells were 
transfected with siRNA duplexes using Hiperfect transfection reagent (Qiagen). Cells were 
seeded at 50% confluency immediately before the transfection complex containing 5 nM siRNA 
oligonucleotides was added. This transfection step was repeated 24 hours later. siRNA 
transfected cells were harvested for subsequent drug treatment 72 hours after the first 
transfection. The siRNA duplexes were purchased from Qiagen and the sequence used to deplete 
Ercc1 was: 5’-GCCCUUAUUCCGAUCUACATT-3’, which has been previously characterized 
in detail (Lan et al., 2004). For negative controls, HeLa cells were transfected with Hiperfect 
with Qiagen AllStars RNAi negative control duplex.  
2.2.4 Cell cycle analysis 
Cells were plated at 50% confluence, then 16 hrs later exposed to 0.3 µM MMC for 12 hrs or left 
untreated. At 12, 24, 48 and 72 hrs after exposure, the cells were fixed with ice cold 70% ethanol 
and stored at 4°C overnight. CHO cells were treated with 5 µM HN2, as described above, and 
samples removed at the stated times for fixing. The fixed cells were washed with PBS, treated 
with RNase A (Roche) at a final concentration of 100 U/ml for 30 min at room temperature and 
then stained with 1 µg/ml propidium iodide in PBS. Cell cycle analysis was performed on Dako 
MoFlo flow cytometer or a Becton Dickinson FACS caliber. 
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2.2.5 Modified Comet assay  
The modified version of the Comet assay for the detection of ICLs was performed exactly as 
previously described (De Silva et al., 2000). 
2.2.6 Cell fractionation 
Cells were fractionated into cytosolic, nuclear and chromatin fractions with a modification of a 
published protocol (Kapetanaki et al., 2006). In brief, cells were trypsinized, pelleted and washed 
twice with PBS. The pellet was vortexed at full speed for 15 sec with 200 µl of CERI reagent 
from the Pierce NE-PER fractionation kit (Pierce Biotech) with Complete™ mini protease 
inhibitor cocktail, then incubated on ice for 10 min. This was followed by addition of 11 µl of 
CERII, vortexing for 5 sec and incubation on ice for 1 min. The mixture was spun down at 
13,000 rpm for 5 min and the supernatant was collected as the cytosolic fraction. The nuclei were 
suspended in extraction buffer (15 mM Tris-HCl pH 7.3, 1 mM EDTA, 0.4 M NaCl, 1 mM 
MgCl2, 10% glycerol, 10 mM β -mercaptoethanol and Complete™ mini protease inhibitor 
cocktail), mixed for 1 hr at 4°C and spun down at 13,000 rpm for 10 min. The supernatant was 
collected as the soluble nuclear fraction and the pellet was suspended in micrococcal nuclease 
buffer (20 mM Tris·HCl pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 0.3 M sucrose, 0.1% 
Triton X-100 and Complete™ mini protease inhibitor cocktail) and digested with 400 U/ml S7 
micrococcal nuclease (Roche) at 37°C for 30 min. The reaction was spun down at 13,000 rpm for 
10 min and supernatant was collected as the chromatin fraction. For CHO and HeLa cells, 
fractionation was performed exactly as described (Qiao et al., 2001).  
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2.2.7 Immunodetection of FANCD2 foci 
C5RO and XP51RO human fibroblasts (Niedernhofer et al., 2006) were plated on glass 
coverslips at 50% confluence, then 16 hrs later exposed to 3 µM MMC for 1 hr or left untreated. 
At 6, 12, 24 and 48 hrs following exposure, cells were fixed as described (Wang et al., 2004) 
with some modifications. Briefly, cells were washed with PBS, permeabilized with ice-cold 
0.5% Triton X-100 in PBS, then fixed with 2% paraformaldehyde and blocked with 5% bovine 
serum albumin at room temperature. FANCD2 was detected by incubation with rabbit polyclonal 
anti-FANCD2 antibody (1:1000, Novus Biologicals) for 90 min at RT and goat anti-rabbit 
Alexa-488 (1:1000, Invitrogen). Images were taken of 20 fields of cells for each genotype. The 
total number of nuclei and the number of nuclei with foci were counted in each field. The sum 
from all fields was used to calculate the percent of nuclei with foci. The experiment was done in 
triplicate. Student’s t-test was used to probe significant differences between cell lines. 
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2.3 RESULTS 
2.3.1 FANCD2 is monoubiquitinated in XPF-ERCC1 and MUS81-EME1 deficient cells
 
Figure 2-1: FANCD2 monoubiquitination in ERCC1-XPF deficient cells 
FANCD2 is monoubiquitinated in XPF-ERCC1 and MUS81-EME1 deficient cells after crosslink 
damage. A, wild type and Ercc1 mutant CHO cells were exposed to 15 µM nitrogen mustard (HN2) for 1 hr, 
then whole cell extracts (WCEs) were collected 18 or 24 hrs later for immunodetection of FANCD2. 
FANCD2-L is the monoubiquitinated protein and FANCD2-S is the non-ubiquitinated form. U indicates cells 
that were untreated. B, wild type HeLa cells were transfected with either control siRNA, or one of two 
siRNAs against hSNM1A as further controls for specificity, or with siRNA against Ercc1. After confirming 
specific knockdown of ERCC1 by immunoblotting, cells were treated with 1 µM MMC for 1 hr and WCEs 
were collected at multiple time points after exposure for immunodetection of FANCD2. C, wild type and 
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Ercc1-/- mouse embryonic fibroblasts (MEFs) were exposed to 0.3 µM mitomycin C (MMC) for 12 hrs then 
WCEs were collected at multiple time points after exposure for immunodetection of FANCD2. D, wild type, 
Mus81-/- and Ercc1-/- mouse embryonic stem (ES) cells were exposed to 3 µM MMC for 1 hr then WCEs were 
collected 24 hrs later for immunodetection of FANCD2. 
 
To determine if XPF-ERCC1 deficiency affects activation of the FA pathway, FANCD2-L 
(monoubiquitinated form) and –S (non-ubiquitinated form) were measured in mutant cells 
exposed to crosslinking agents. Wild-type and Ercc1 mutant Chinese hamster ovary (CHO) cells 
were exposed to the crosslinking agent nitrogen mustard (HN2) for 1 hr, then WCEs collected 18 
or 24 hrs later. The levels of FANCD2-L were similarly increased in both cell types after 
exposure to HN2 relative to untreated samples (Figure 2-1A and Figure 2-5A). This was 
confirmed in an isogenic pair of human cell lines by knocking down ERCC1 expression in HeLa 
cells using siRNA and exposing them to a different crosslinking agent, MMC (Figure 2-1B and 
Fi. 2-5B). Comparable results were obtained with Ercc1-/- mouse embryonic fibroblasts (MEFs) 
exposed to MMC (Figure 2-1C and Figure 2-5C). Since XPF-ERCC1 nuclease appeared not to 
be required for FA pathway activation, we also screened cells deficient in MUS81, a second 
nuclease required for ICL repair (Hanada et al., 2006). Mouse embryonic stem cells (ES) 
genetically deleted for either Ercc1 or Mus81 were exposed to MMC for 1 hr then WCEs 
collected 24 hrs later. Immunodetection of FANCD2 revealed increased levels of FANCD2-L in 
all cells exposed to the crosslinking agents relative to the untreated cells (Figure 2-1D). These 
data demonstrate that FANCD2 is monoubiquitinated in response to crosslink damage in the 
absence of XPF-ERCC1 or MUS81-EME1. This indicates that nucleolytic processing of 
crosslinks by MUS81-EME1 or XPF-ERCC1 is not necessary for FA pathway activation, as 
defined by FANCD2 monoubiquitination. 
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2.3.2 FA pathway activation persists in XPF-ERCC1 deficient cells 
 
Figure 2-2: Persistence of FANCD2 monoubiquitination in ERCC1-XPF deficient cells 
Monoubiquitination of FANCD2 persists in XPF-ERCC1 deficient cells. A, AA8 (wild type), UV135 
(Xpg mutant), UV96 (Ercc1 mutant) and UV47 (Xpf mutant) CHO cells were exposed to 1 µM MMC for 12 hr 
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or 5 µ M nitrogen mustard (HN2) for 1 hr then WCEs were collected at multiple time points following 
exposure for immunodetection of FANCD2. U indicates cells that were untreated. B, wild type, XP-A 
(XP25RO) and XP-F (XP51RO and XP42RO) immortalized human fibroblasts were exposed to 0.3 µM MMC 
for 12 hrs then WCEs were collected at multiple time points after exposure for immunodetection of FANCD2. 
C, CHO cells were treated as described in A then fixed at the same time points, and stained with propidium 
iodide for cell cycle analysis by flow cytometry. D, The efficiency of unhooking of interstrand crosslinks 
determined by modified Comet assay, following 1 hr treatment with 5 µM HN2 in Xpg, Xpf and Ercc1 mutant 
and wild type parent cell lines. 
 
Although FANCD2 is monoubiquitinated in XPF-ERCC1 deficient cells, initial data from the 
MEFs suggested that FANCD2-L levels remained elevated longer in Ercc1-/- cells exposed to 
MMC compared to wild-type cells (Figure 2-1C and Figure 2-5C). To investigate this further, 
wild-type and mutant CHO cells and human fibroblasts were exposed to MMC or HN2, and 
FANCD2 was visualized by immunoblot at multiple time points following DNA damage. Both 
MMC and HN2 induced an increase in the ratio of FANCD2-L to FANCD2-S in wild-type and 
NER deficient Xpg mutant CHO cells (Figure 2-2A). By 48 hrs after HN2 or MMC exposure, 
FANCD2-L levels returned to near-normal in these cell lines. In contrast, the ratio of FANCD2-
L to FANCD2-S was still elevated in both Xpf and Ercc1 mutant CHO cells at 48 hrs after 
exposure to HN2 or MMC (Figure 2-2A and Figure 2-5D). The results were recapitulated in cells 
derived from human XP patients (Figure 2-2B). In wild-type and NER deficient XP-A human 
fibroblasts, MMC induced a rapid increase in the ratio of FANCD2-L to FANCD2-S that 
persisted for 24 hrs. The levels of monoubiquitinated FANCD2 returned to those of untreated 
cells by 48 hrs. In two different XP-F cell lines, the ratio of FANCD-L to –S was increased by 
MMC, like wild-type cells. However, in the XPF-ERCC1 deficient cells, the ratio of FANCD2-L 
to -S remained elevated at 48 hrs after exposure to MMC (Figure 2-2B and Figure 2-5E). This 
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suggests that in the absence of XPF-ERCC1 the FA pathway remains activated in response to 
crosslink damage.  
Because FANCD2 monoubiquitination is cell cycle-dependent (Kim et al., 2008a), the 
cell cycle profile of the CHO cell lines was measured at multiple time points after exposure to 
crosslinking agents (Figure 2-2C). HN2 and MMC caused an accumulation of cells in S and 
G2/M phases at 12 and 18 hrs in all cells. By 48 hrs following MMC treatment, some wild-type 
and Xpg mutant cells had escaped G2/M arrest, but XPF-ERCC1 defective cells remained 
arrested in late S and G2/M. Therefore, persistent FANCD2-L correlates with G2/M 
accumulation. The Xpg mutant cells were somewhat slower to escape the G2/M arrest compared 
to wild-type cells, and this might be attributable to the role of NER in repairing the monoadducts 
produced by crosslinking agents. The persistence of FANCD2-L also correlates with impaired 
unhooking of crosslink damage (Figure 2-2D). The modified comet assay (De Silva et al., 2000) 
was used to measure nucleolytic processing of crosslink damage in CHO cells following HN2 
exposure. In wild-type and Xpg mutant cells crosslink unhooking was greater than 85% at 48 hrs. 
In contrast, in Ercc1 and Xpf mutant cells in which FANCD2 monoubiquitination persisted, 
crosslink unhooking was only approximately 40% at 48 hrs. These data indicate that nucleolytic 
processing of ICLs coincides with the deactivation of FA pathway, marked by a decrease in the 
FANCD2-L to FANCD2-S ratio, and is associated with escape from G2/M. 
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2.3.3 FANCD2 foci are reduced in XPF-ERCC1 deficient human fibroblasts  
 
Figure 2-3: FANCD2 focus formation in ERCC1-XPF deficient cells in response to ICL damage 
FANCD2 focus formation is impaired in XPF-ERCC1 deficient cells. Wild type (C5RO) and XP-F 
(XP51RO) human fibroblasts were seeded on glass coverslips. Sixteen hours later the cells were exposed to 3 
µM MMC for 1 hr, then fixed at multiple time points. FANCD2 was detected by immunofluorescence. Cells 
with FANCD2 foci were counted. Representative images are shown and the average of three experiments 
plotted. A paired Student’s t-test was used to calculate significance. 
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Another way to quantify FA pathway activation is to measure chromatin bound FANCD2 
(Oestergaard et al., 2007). Surprisingly, in human fibroblasts the number of cells with FANCD2 
foci was significantly reduced in the XPF-ERCC1 deficient cell line (Figure 2-3). We measured 
FANCD2 foci in human fibroblasts exposed to MMC, after detergent extraction of soluble 
proteins. FANCD2 foci were detected in approximately 15% of untreated wild-type and XPF 
mutant cells. Twelve hours after exposure to MMC, 40% of wild-type cells had FANCD2 foci 
whereas 29% of XPF mutant cells had foci (p=0.025) and 24 hrs after the exposure, 42% of wild-
type cells and 36% of XPF mutant cells had FANCD2 foci (p=0.001). By 48 hrs after crosslink 
damage the fraction of cells with FANCD2 foci had returned to normal in both cell types. These 
data suggest that although FANCD2 is efficiently ubiquitinated in XPF-ERCC1 deficient cells in 
response to crosslink damage, the localization of FANCD2 to the chromatin is impaired, a 
critical step for subsequent HR-mediated repair of replication induced DSBs. 
2.3.4 Chromatin bound FANCD2 is reduced in XPF-ERCC1 deficient cells 
FANCD2 levels were normal in XPF-ERCC1 deficient cells exposed to crosslinking agents, yet 
chromatin-bound FANCD2 focus formation was diminished, suggesting aberrant subcellular 
localization of FANCD2 in the absence of this nuclease. To further explore this, ERCC1 was 
depleted in HeLa cells by siRNA; the cells were then exposed to HN2 and fractionated. 
Immunodetection of FANCD2 in WCEs revealed that, as previously observed (Figure 2-1B), 
FANCD2 was efficiently monoubiquitinated in both control and ERCC1-depleted cells (Figure 
2-4A and Figure 2-5F). In control cells, the level of FANCD2-L in the chromatin fraction 
increased dramatically following exposure of the cells to HN2 (Figure 2-4A). In contrast, in 
  45 
ERCC1-depleted cells, the amount of FANCD2-L in the chromatin fraction did not increase 
following exposure of cells to HN2, but instead was elevated in the soluble nuclear fraction 
(Figure 2-4A).   
 
Figure 2-4: Chromatin binding of FANCD2 in ERCC1-XPF deficient cells 
Chromatin localization of FANCD2 is impaired in XPF-ERCC1 deficient cells exposed to 
crosslinking agents, but not ionizing radiation. A, HeLa cells depleted for ERCC1, or mock depleted with a 
control siRNA duplex were treated with 1 µM HN2 for 1 hr. At 18 hrs after exposure WCEs were prepared 
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or cells were fractionated to isolate the soluble nuclear and chromatin bound protein fractions. Samples were 
immunoblotted for FANCD2. Immunodetection of ORC2 (origin recognition complex 2) was used as a 
loading control for chromatin-bound protein and GRB2 for cytoplasmic protein. B, wild type (C5RO) and 
XP-F (XP51RO) human fibroblasts were exposed to 3 µM MMC for 1 hr then fractionated 12 hrs later. The 
fractions were immunoblotted for FANCD2. Nucleophosmin and histone H3 were used as loading controls for 
the soluble nuclear and chromatin fractions, respectively. C, wild type and Ercc1-/- mouse embryonic 
fibroblasts (MEFs) were exposed to 3 µM MMC for 1 hr and fractionated at multiple time points after 
exposure. Fractions were immunoblotted for FANCD2 and the loading controls. D, Wild type (IB10) and 
Ercc1-/- (Clone 49) mouse embryonic stem (ES) cells were exposed to 3 µM MMC for 1 hr and fractionated at 
24 hrs after exposure. Fractions were immunoblotted for FANCD2 with TATA binding protein (TBP) as the 
loading control. E, wild type and Xpf mutant CHO cells were exposed to 5 µM HN2 for 1 hr or 10 Gy of 
ionizing radiation. Cells were processed as described in A at 18 and 24 hrs after radiation and samples were 
immunoblotted for FANCD2. Tubulin was used as loading control for WCE and ORC2 was used as loading 
control for the chromatin fraction.  
 
In human fibroblasts, the level of FANCD2-L was comparable for XP-F and wild-type 
cells before and after exposure to MMC (Figure 2-4B). However, the amount of FANCD2 
detected in the chromatin fraction of XP-F fibroblasts treated with MMC was substantially lower 
than that detected in normal human fibroblasts (Figure 2-4B and Figure 2-5G). This is consistent 
with the observation that XP-F cells had significantly fewer FANCD2 foci than wild-type cells 
after MMC treatment (Figure 2-3). Similar results were obtained using congenic Ercc1-/- MEFs 
exposed to MMC (Figure 2-4C and Figure 2-5H), where again there was less chromatin-bound 
FANCD2 in the knock-out cells compared to wild-type in response to crosslink damage. The 
subcellular localization of FANCD2 was less dramatically affected in ES cells (Ercc1-/- and 
Mus81-/-) than fibroblasts (Figure 2-4D). One possible explanation is that ES cells differ 
dramatically from fibroblasts in their cell cycle profile and checkpoint responses to crosslink 
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damage (Supplemental Figure 2-2A-C). Finally, an equivalent level of FANCD2-L was detected 
in wild-type and Xpf mutant CHO cells exposed to HN2 (Figure 2-4E). However, substantially 
less FANCD2-L was detected in the chromatin fraction of the mutant cells. In contrast, 
chromatin localization of FANCD2-L was not impaired in Xpf mutant cells exposed to ionizing 
radiation (Figure 2-4E). This indicates that the aberrant subcellular localization of FANCD2-L 
seen in XPF-ERCC1 deficient cells was specific for ICLs and not other forms of DNA damage, 
such as direct DSBs, where XPF-ERCC1 is not required prior to HR-mediated repair (Ahmad et 
al., 2008).  
Taken together these data, obtained in three mammalian cell systems exposed to two 
different crosslinking agents, support the conclusion that FANCD2 is not stably localized to the 
chromatin in the absence of XPF-ERCC1. This suggests that nucleolytic processing of crosslink 
damage is required for the stable accumulation of FANCD2 at or near the sites of damage. The 
data also imply that FANCD2 monoubiquitination does not always correlate with chromatin 
localization and should be considered as distinct steps in the response to crosslink damage. 
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Figure 2-5: Immunoblot band intensities 
Graphical representation of FANCD2 band intensities in immunoblots, measured by densitometry: 
A-F, ratio of FANCD2-L and FANCD2-S band intensities. G and H, total chromatin bound FANCD2 
(FANCD2-L + FANCD2-S) corrected by the loading control. 
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Figure 2-6: Cell cycle profile of ERCC1-XPF cells after ICL damage 
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Crosslink damage induces an S/G2 arrest that persists in ERCC1-XPF deficient cells. A, wild type 
(C5RO) and XPF mutant (XP51RO) immortalized human fibroblasts were exposed to 3 µM MMC for 1 hr 
and harvested at multiple time points after exposure. Cells were then fixed and stained with propidium 
iodide, and subjected to flow cytometry for cell cycle analysis. B, wild type and Ercc1-/- mouse embryonic 
fibroblasts were processed as above. C, wild type (IB10) and Ercc1-/-  (Clone 49) mouse ES cells were 
processed as above. 
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2.4  DISCUSSION 
Two sets of proteins that are critical for the response to and repair of ICLs are the FA family of 
proteins and the XPF-ERCC1 complex (McHugh et al., 2001; Niedernhofer et al., 2005). 
Whether or not these proteins function in the same DNA damage detection and repair mechanism 
is not established. A significant body of biochemical and cellular data indicates an essential role 
for XPF-ERCC1 endonuclease in the unhooking of ICLs (De Silva et al., 2000; Kuraoka et al., 
2000). However, it is not known if unhooking of ICLs must occur prior to activation of the FA 
pathway. Our studies revealed that XPF-ERCC1 nuclease is not required for activation of the FA 
pathway, as defined by the monoubiquitination of FANCD2. In the same experiments, we 
confirmed that both XPF and ERCC1 are required for efficient ICL unhooking using the 
modified comet assay. Thus nucleolytic processing of ICLs by XPF-ERCC1 is not a pre-requisite 
for FA pathway activation. This is consistent with the results of numerous other laboratories, 
indicating that replisome stalling at DNA lesions and secondary structures, as occurs with ICLs, 
is sufficient to generate the signal which ultimately leads to FANCD2 ubiquitination (D'Andrea 
and Grompe, 2003; Gregory et al., 2003; Montes de Oca et al., 2005). Given that ATR activation 
is also required for the timely ubiquitination of FANCD2 in response to ICLs (Andreassen et al., 
2004), it is tempting to speculate that tracts of single-stranded DNA (ssDNA) that occur at 
stalled replisomes are what trigger ATR-dependent FANCD2 monoubiquitination. In the case of 
ICLs, ssDNA likely results from nucleolytic processing of stalled forks rather than uncoupling of 
leading and lagging strand synthesis (Paulsen and Cimprich, 2007), which is what activates ATR 
when replication is blocked by lesions that affect only one strand of DNA. 
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Figure 2-7: A model of crosslink repair 
Model of how XPF-ERCC1 and MUS81-EME1 nucleases function in the same S-phase specific DNA 
interstrand crosslink repair mechanism as the Fanconi anemia proteins. See text for more details. 
 
Although XPF-ERCC1 dependent nucleolytic processing of ICLs is not required for FA 
pathway activation, our data did reveal a difference in the kinetics of FANCD2 modification in 
XPF-ERCC1 deficient cells. These nuclease-deficient cells show a persistence of 
monoubiquitinated FANCD2 in whole cell extracts following ICL induction. In contrast to our 
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results, McCabe et al reported decreased monoubiquitination of FANCD2 in cells depleted of 
ERCC1 by siRNA (McCabe et al., 2008). However, like us, these authors did observe that MMC 
causes an induction of FANCD2 monoubiquitination in ERCC1-depleted cells and that the 
relative increase in the ratio of FANCD2-L to -S was similar in ERCC1-depleted and control 
cells upon crosslink damage. We observed persistent FANCD2 monoubiquitination in XPF-
ERCC1 deficient cells from three species in response to two different crosslinking agents. 
Prolonged FANCD2 monoubiquitination has not previously been reported in other crosslink 
sensitive mutants, suggesting that incision of crosslinked DNA by XPF-ERCC1 is essential for 
the repair of ICLs and termination of the DNA damage response.  
In addition, chromatin localization of FANCD2 in response to crosslink damage is 
impaired in XPF-ERCC1 deficient cells, as demonstrated by cellular fractionation and FANCD2 
foci formation. This suggests that stable association of monoubiquitinated FANCD2 with 
chromatin requires (at a minimum) an unhooked ICL. Indeed, the persistent FANCD2-L 
observed in Xpf and Ercc1 mutant WCEs might reflect continued attempts to target FANCD2 to 
sites of damage in chromatin, which are non-productive when crosslinked DNA is not incised.  
The XPF-ERCC1-related nuclease, MUS81-EME1 is also implicated in ICL repair by 
virtue of the hypersensitivity of Mus81-/- and Eme1-/- mouse cells to crosslinking agents (Hanada 
et al., 2006). Specifically, MUS81 is required for the cleavage of replication forks stalled by 
ICLs, producing DSBs with one accessible end (Hanada et al., 2007; Hanada et al., 2006). 
However, ICL-induced monoubiquitination of FANCD2 is normal in Mus81-/- cells (Figure 2-1) 
and genetic disruption of FANCB and MUS81 does not render cells hypersensitive to 
crosslinking agents relative to deletion of FANCB alone (Nomura et al., 2007). These data 
support the conclusion that the generation of DSBs at ICLs during S-phase by MUS81-EME1 is 
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not a pre-requisite for activation of FANCD2. Taken together, these data suggest a model for 
ICL repair (Figure 2-7; see also a recent review by Thompson and Hinz (Thompson and Hinz, 
2009)) in which stalling of a replication fork at an ICL leads to the formation of a DSB created 
by MUS81-EME1 nuclease. Fork stalling, but not the generation of a DSB, is sufficient for 
activation of ATR and the monoubiquitination of FANCD2. However, in the absence of 
unhooking of the ICL by XPF-ERCC1, FANCD2 and, therefore, presumably the HR machinery 
do not stably associate at the sites of damage. This results in failure to repair ICL-dependent 
DSBs in XPF-ERCC1 deficient cells (Niedernhofer et al., 2004).  
The data presented herein demonstrate that there is not an absolute correlation between 
the level of monoubiquitinated FANCD2 and its chromatin association. In XPF-ERCC1 deficient 
cells in which ICL-dependent DSBs are not repaired (Niedernhofer et al., 2004), the levels of 
monoubiquitinated FANCD2 persist longer than in wild-type cells after crosslink damage, but 
chromatin localization of FANCD2 is reduced. This suggests that in the absence of ICL repair, 
damage signalling persists. In accordance, it was recently reported that FANCD2 
deubiquitination by USP1 (Nijman et al., 2005), is required for efficient ICL repair (Oestergaard 
et al., 2007). Thus when chromatin association of FANCD2 is compromised, for instance in the 
absence of ICL unhooking by XPF-ERCC1, deubiquitination of FANCD2 by USP1 does not 
occur. This is supported by the observation that FANCD2 deubiquitination is concurrent with 
release of FANCD2 from chromatin (Oestergaard et al., 2007). The eviction of FANCD2 from 
chromatin likely coincides with the recruitment of factors that undertake post-unhooking steps of 
ICL repair, including homologous recombination-mediated DSB repair and translesion synthesis 
to fill the gap created by ICL unhooking (Niedzwiedz et al., 2004; Wang et al., 2004). 
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3.0  MISLOCALIZATION OF DNA REPAIR NUCLEASE XPF-ERCC1: THE 
MOLECULAR BASIS FOR REDUCED DNA REPAIR IN XP-F PATIENTS 
This chapter is under review for publication in PLoS Genetics: 
Ahmad, A.*, Enzlin, J.H.*, Bhagwat, N.R.*, Wijgers, N., Raams, A., Appledorn, E., 
Theil, A.F., Hoeijmakers, J.H.J., Vermeulen, W., Jaspers, N.G.J., Scharer, O.D. and L.J. 
Niedernhofer (2009) Aberrant sub-cellular localization of DNA repair protein XPF: the 
molecular basis for reduced DNA repair in XP-F patients. (*Contributed equally) 
3.1 INTRODUCTION 
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease characterized by 
photosensitivity and greater than a 1000-fold increased risk of skin cancer in sun-exposed areas 
of the skin (Kraemer et al., 1987). In approximately 20% of patients, there is also progressive 
neurodegeneration leading to loss of coordination motion, vision and hearing (Nouspikel, 2008; 
Robbins et al., 1991). XP is caused by mutations in genes that encode proteins required for 
nucleotide excision repair (NER) of DNA. Eight complementation groups of XP have been 
identified based on fusion studies with XP patient cells. These complementation groups include 
XP-A through XP-G and a variant, XP-V. The severity of XP varies tremendously, with 
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diagnosis occurring anywhere from infancy to adulthood. The severity of the disease is 
determined largely by which gene is mutated and to what extent the mutation affects NER.  
NER removes helix-distorting lesions in DNA, for example cyclobutane pyrimidine 
dimers (CPDs) and pyrimidine pyrimidone photoproducts (6-4PPs) caused by the ultraviolet 
(UV) component of sunlight (Gillet and Scharer, 2006).  There are two ways by which DNA 
damage is recognized in NER. Lesions anywhere in the genome can be recognized by the 
complex XPC-RAD23B (Sugasawa et al., 1998; Volker et al., 2001). For some lesions, this is 
facilitated by a second complex XPE/DDB2-DDB1 (Sugasawa, 2006). Alternatively, lesions that 
occur in the coding strand of DNA, within transcribed regions, can trigger NER if they stall 
progression of RNA polymerase II (Hanawalt and Spivak, 2008; Laine and Egly, 2006). This 
requires CSA, CSB and XAB2 (Henning et al., 1995; Nakatsu et al., 2000; Troelstra et al., 
1992). Once the damage is recognized, the subsequent steps of damage excision are believed to 
be uniform. The basal transcription factor TFIIH is recruited to the site of helix-distortion to 
unwind the DNA around the lesion, using two of its ten subunits, XPB and XPD (Evans et al., 
1997; Laine and Egly, 2006). RPA and XPA bind the unwound repair intermediate to stabilize it 
and recruit subsequent factors. The damaged strand of DNA is then incised by two structure-
specific endonucleases, the heterodimer of XPF-ERCC1 and XPG, which cut 5’ and 3’ of the 
lesion, respectively (Bardwell et al., 1994; O'Donovan et al., 1994; Sijbers et al., 1996a; 
Staresincic et al., 2009). This leads to removal of the lesion as part of a 24-32 base 
oligonucleotide. The resultant gap is filled by the replication machinery including RPA, PCNA, 
RF-C, DNA polymerase δ/ε, and the backbone is sealed by DNA LIGI or LIGIIIα-XRCC3 
(Moser et al., 2007; Ogi and Lehmann, 2006; Shivji et al., 1995).   
  57 
XPF-ERCC1 is a highly conserved endonuclease that nicks double-stranded DNA 5’ to a 
junction with single-stranded DNA (de Laat et al., 1998a). In addition to NER, XPF-ERCC1 is 
involved in the repair of DNA interstrand crosslinks (ICL) (Niedernhofer et al., 2004) and 
double-strand break (DSB) repair (Ahmad et al., 2008). XPF and ERCC1 are paralogs thought to 
have arisen by gene duplication of the conserved nuclease and helix-hairpin helix protein-
interaction domains (Gaillard and Wood, 2001).  The proteins interact via their C-terminal helix-
hairpin-helix domains and this interaction is required to stabilize both proteins in vivo 
(Biggerstaff et al., 1993; de Laat et al., 1998b). XPF contains the nuclease catalytic domain 
(Enzlin and Scharer, 2002), whereas ERCC1 mediates the interaction with XPA and recruitment 
to NER complexes (Li et al., 1994; Tsodikov et al., 2007). Unlike NER-specific proteins XPA 
and XPC, XPF-ERCC1 appears to be essential for human development or viability since no early 
nonsense or frameshift mutations in either gene have yet been identified.  
XP-A and XP-C are among the most common complementation groups in XP (Zeng et 
al., 1997). XP-C patients have severe skin abnormalities but generally lack neurological 
symptoms (Moriwaki and Kraemer, 2001). In contrast, XP-A patients show profound 
neurodegeneration, in addition to cutaneous features (Kraemer et al., 1987). XP-F patients 
typically have very mild cutaneous features of XP, including late onset of skin cancer, but often 
have neurological complications. It was recently discovered that mutations in XPF can lead to a 
second disease, XFE progeroid syndrome (short for XPF-ERCC1), characterized by spontaneous, 
accelerated aging of multiple organ systems including the nervous system (Niedernhofer et al., 
2006). It is highly unlikely that this disease is caused by a defect in NER alone, but instead is 
caused by additional defects in other XPF-ERCC1 dependent DNA repair mechanisms, such as 
ICL or DSB repair. 
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Genetic deletion of Xpf or Ercc1 in the mouse causes accelerated aging and a severely 
reduced lifespan of 3-4 weeks (Tian et al., 2004; Weeda et al., 1997). However, mice expressing 
10% of the normal level of XPF-ERCC1 have a less severe phenotype and live 28 weeks (Weeda 
et al., 1997). This leads to the hypothesis that the level of the XPF-ERCC1 nuclease available to 
engage in DNA repair mechanisms in the cell nucleus is the primary determinant in disease 
severity associated with mutations in XPF. Herein, we test this hypothesis using human patient 
cell lines and make the surprising discovery that in patients with mutations in XPF, the XPF-
ERCC1 DNA repair complex is frequently mislocalized into the cytoplasmic compartment of 
cells, where it cannot participate in DNA repair. 
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3.2 RESULTS 
3.2.1 Characterization of R153P-XPF-ERCC1 activity in vitro 
We first asked if mutations in XPF that cause mild or severe disease differentially affect the 
biochemical properties of XPF-ERCC1. To test this, we compared the biochemical properties of 
XPF-ERCC1 from two patients, XP42RO (an XP-F patient homozygous for R799W in XPF 
(Sijbers et al., 1998)) and XP51RO (a patient with XFE progeroid syndrome homozygous for 
R153P in XPF (Niedernhofer et al., 2006)) to that of wild type XPF-ERCC1. Recombinant XPF-
ERCC1, XPF R153P-ERCC1 and XPF R799W-ERCC1 were purified from baculovirus-infected Sf9 
insect cells using a His6 tag on ERCC1. We previously reported [25] that our purified 
preparations of XPFWT-ERCC1 elute from a gel-filtration column in three fractions:  (1) a minor 
fraction in the void volume (~45 ml) containing aggregated, inactive protein; (2) active 
heterodimeric XPF-ERCC1 at ~65 ml, which corresponds to a molecular weight of ~ 200 kD, as 
expected, and (3) monomeric ERCC1, which peaks at ~78 mL, which corresponds to ~50 kD.  
Recombinant XPFWT-ERCC1 eluted as expected (Figure 3-1A). In contrast, the majority of the 
mutant XPF-ERCC1 proteins eluted at ~45 mL in the void volume of the column, indicating that 
it was aggregated, likely due to protein misfolding. Nonetheless, we were able to purify a small 
amount of XPF R153P-ERCC1 and XPF R799W-ERCC1 from the fractions eluting at 65 ml (Figure 
3-1B), indicating that at least some of the mutant protein formed a heterodimer, indicating that it 
is likely to be properly folded. SDS PAGE analysis of the complexes purified in an additional 
step over a heparin column, revealed dramatically reduced yields of the complexes of XPFR153P-
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ERCC1 and XPFR799W-ERCC1 compared to XPFWT-ERCC1 (Figure 3-1B). Similarly, in vivo, 
the amount of XPF detectable by immunoblot was substantially reduced in cells harboring the 
XPFR153P and XPFR799W mutations (XP51RO and XP42RO, respectively) compared to wt cells 
(C5RO) (Figure 3-1C). 
The catalytic activity of the purified heterodimers was investigated by measuring their 
ability to incise a 32P-end-labeled stem–loop DNA substrate at the single-strand/double-strand 
DNA junction in the presence of 0.4 mM MnCl2 or 2 mM MgCl2 and a 2-fold molar excess of 
protein over substrate. We previously observed that mutant XPF-ERCC1 complexes tend to be 
more active in the presence of Mn2+, since this metal has less stringent requirements for the 
proper alignment of the active site residues (Enzlin and Scharer, 2002). Consistent with this, 
reactions in the presence of Mn2+ yielded the greatest activity leading to greater than 80% 
cleavage of the stem-loop substrate by wild type XPF-ERCC1 (Figure 3-1D). Incision was 
reduced to approximately 50% of the total substrate for XPF R153P-ERCC1 and XPF R799W-
ERCC1. When Mg2+ was used as a cation, incision activity of wild type XPF-ERCC1 was not 
affected. However, catalytic activity of both mutant protein complexes was dramatically reduced 
in the presence of Mg2+ relative to Mn2+.  Notably, there was no dramatic difference in 
enzymatic activity between XPFR153P-ERCC1 and XPFR799W-ERCC1 on stem-loop DNA 
substrates, indicating that the biochemical basis for the more severe phenotype associated with 
the R153P mutation is unlikely to be a simple loss of catalytic activity. 
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Figure 3-1: Biochemical characterization of XPFR153P-ERCC1 and XPFR799W-ERCC1 mutants 
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A, Gel filtration profiles from the purification of recombinant XPF-ERCC1, XPF R153P-ERCC1 and 
XPF R799W-ERCC1 from baculovirus-infected Sf9 insect cells using a His6 tag on ERCC1. Aggregated proteins 
elute at ~45 ml in the void volume of the column, heterodimeric XPF-ERCC1 elutes at ~65 ml, corresponding 
to ~ 200 kD, and monomeric ERCC1 elutes at ~78 ml (~50kD). B, SDS PAGE analysis of purified protein 
complexes. Lane 1, 3 and 5 (labeled D): XPF-ERCC1, XPF R153P-ERCC1 and XPF R799W-ERCC1, respectively, 
after purification over NTA-agarose, gel filtration and heparin columns. Lanes 2 and 4 (labeled A) show the 
proteins present in the fractions eluting at 45 ml in the gel filtration column step of XPF R153P-ERCC1 and 
XPF R799W-ERCC1, respectively. C, Immunodetection of XPF in normal (C5RO) and XPF mutant cells. The 
star indicates the migration of a cross-reactive band demonstrating equal loading (Niedernhofer et al., 2006).  
D, Incision activities of XPF-ERCC1, XPF R153P-ERCC1 and XPF R799W-ERCC1 (200 fmol) on a 5’-32P-labeled 
stem-loop DNA substrate (100 fmol) in the presence of either 0.4 mM MnCl2 (lanes 2, 4 and 6) or 2 mM 
MgCl2 (lanes 3, 5 and 7). Reactions were analyzed on a 15% denaturing polyacrylamide gel. The 46-mer 
substrate and 9-10-mer products are indicated. E, In vitro NER activity of wt XPF-ERCC1, R153P-XPF-
ERCC1 and R799W-XPF-ERCC1. A plasmid containing a single 1,3-intrastrand d(GpTpG)-cisplatin adduct 
was incubated with 500 µg of whole cell extracts expressing XPF-ERCC1, R153P-XPF-ERCC1 and R799-XPF-
ERCC1. The excised fragments were detected by radiolabeled probe as described in Materials and Methods. 
The position of the 35 and 27 nucleotide marker bands from MspI digested pBR322 plasmid are indicated. 
 
To further probe the catalytic activity of these mutant protein complexes, their ability to 
incise an intrastrand cisplatin adduct was measured. A plasmid containing a single 1,3-
intrastrand d(GpTpG)-cisplatin adduct was incubated with 500 µ g of whole cell extracts 
expressing XPF-ERCC1, XPFR153P-ERCC1 and XPFR799W-ERCC1. Incision yields radiolabeled 
fragments of 27-35 nucleotides in length, corresponding to the range of excision products in 
NER (Hohl et al., 2007; Moggs et al., 1996). Incision was observed in WCEs with XPF-ERCC1 
and to a lesser extent XPFR799W-ERCC1 (Figure 3-1E, lanes 2 and 4, respectively).  No NER 
incision was observed in extracts from cells complemented with XPFR153P-ERCC1. These 
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observations raise the possibility that the mutant heterodimers do not properly interact with the 
NER machinery. The loss of activity may however also be due to the fact that we were only able 
to obtain the mutant proteins in very low concentrations, which we have found to be problematic 
in NER assays in WCEs in other cases (JHE and ODS, unpublished observations). 
3.2.2 Immunolocalization of XPF protein   
R153P is situated in a lysine-rich domain of XPF that might be part of a complex nuclear 
localization sequence (NLS). Thus we next asked if mutant XPF was mislocalized in cells. 
Differential immunofluorescence was used to compare the sub-cellular localization of XPF in 
normal and XPF mutant cell lines in a single sample (Vermeulen et al., 2000). Primary 
fibroblasts derived from an unaffected individual, an XP patient (XP42RO; XPFR799W) and an 
XFE patient (XP51RO; XPFR153P) were cultured in the presence of different sized beads in order 
to differentially label them.  Subsequently, the labeled cell lines were co-cultured, fixed and 
immunostained on a single glass coverslip. XPF was detected exclusively in the nucleus of 
normal fibroblasts (Figure 3-2A, upper panels). In the same sample, XPF was detected in the 
cytoplasm of XP51RO cells (R153P) creating a negative outline of the cell nucleus. In XP42RO 
cells (R799W), the XPF signal was pancellular so that the nucleus and cytoplasm could not be 
distinguished from one another. To explore this further, we used immunofluorescence to detect 
XPF in additional XP-F patient cell lines and discovered that in all XPF mutant cell lines XPF 
was frequently detected in the cytoplasm. In fact, in all cases XPF mutant cell lines could be 
discriminated from normal fibroblasts by the staining pattern of the cell population. This was 
true irrespective of the antibody used [monoclonal 3F2 (Cancer Research UK), monoclonal Ab-1  
  64 
 
Figure 3-2: Differential immunofluorescence of cells from patients with XPF mutations 
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Fibroblasts from patients with mutations in XPF and a normal control were grown in the presence of 
different size beads.  After 24 hr the cultures were washed to remove extracellular beads, mixed and co-plated 
on glass coverslips.  The next day, the cells were fixed and immunostained as indicated.  Cells were stained 
with Dapi to identify nuclei and examined by phase contrast microscopy to identify the cell type by their bead 
content and by fluorescence microscopy for immunodetection of XPF or ERCC1.  A, Analysis of XPF protein 
sub-cellular localization. Cells from an unaffected individual were labeled with 2 µM beads; Xpf mutant cells 
were labeled with 0.8 µM beads. B, Analysis of ERCC1 subcellular localization in patients with mutations in 
XPF.  C, Immunodetection of XPF and ERCC1 in nuclear and cytoplasmic fractions of normal fibroblasts 
(C5RO) and Xpf mutant cells (XP51RO). Tubulin is used as a loading control of the cytoplasmic fraction. 
Nucleophosmin is used as a loading control for the nuclear fraction. D, Quantitation of the fraction of cells 
containing exclusively nuclear XPF-ERCC1, XPF-ERCC1 in the nucleus and cytoplasm (pancellular) or 
exclusively cytoplasmic complex, as determined from immunofluorescence images (n≥100 cells per cell line). 
 
(Neomarkers), or polyclonal anti-XPF (Erasmus Medical Centre)] (data not shown). This 
indicates that mislocalization of XPF in the cytoplasm is a common consequence of XPF 
mutation.  
This observation raised the possibility that misfolding of mutant XPF caused abnormal 
subcellular localization of the protein. To address this, we immunostained XPF mutant cells for 
ERCC1, the obligate binding partner of XPF. ERCC1 was detected in the nucleus of normal (wt) 
fibroblasts. However, like XPF, ERCC1 was frequently detected exclusively in the cytoplasm of 
XPF mutant cells or pancellular (Figure 3-2B).  All eight XPF mutant cells lines tested were 
readily distinguished from wt cells by the ERCC1 staining pattern. Furthermore the staining 
pattern for ERCC1 and XPF correlated for each cell line. This indicates that ERCC1 interacts 
with the mutant XPF proteins, indicating that mutant XPF is not entirely misfolded or degraded. 
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Furthermore, these results demonstrate that ERCC1 enters the nucleus as a heterodimer with 
XPF and that mutant XPF protein fails to target ERCC1 to the nucleus. 
To further test this, wt and XPFR153P fibroblasts were fractionated and nuclear and 
cytoplasmic XPF-ERCC1 was detected by immunoblot (Figure 3-2C). In wt cells, XPF-ERCC1 
is predominantly nuclear. XPF-ERCC1 was detected in the cytoplasmic fraction, but to an extent 
proportional to nuclear contamination, as determined by immunodetection of the nuclear protein 
nucleophosmin. In the XP51RO cells, substantially more XPF and ERCC1 were detected in the 
cytoplasm than in the nucleus. Degradation products of both proteins are commonly detected on 
immunoblot, but were not overrepresented in the mutant cell line. Similar results were obtained 
for other XPF mutant cell lines (XP24BR, XP26BR and XP32BR) and using other antibodies 
against XPF and ERCC1 (data not shown). These data confirm the immunofluorescence data and 
support the conclusion that mislocalization of XPF-ERCC1 in the cytoplasm occurs in XPF 
mutant cells. 
Remarkably, mislocalization of XPF-ERCC1 does not occur in all XPF mutant cells 
within a population. To quantify the phenomena, the fraction of cells with exclusively nuclear, 
exclusively cytoplasmic or pancellular XPF-ERCC1 was determined from immunofluorescence 
images (Figure 3-2D). In wt fibroblasts, 93% of cells have XPF-ERCC1 only in the nucleus and 
never is the complex seen exclusively in the cytoplasm. In all of the Xpf mutant cell lines, XPF-
ERCC1 was detected exclusively in the cytoplasm of some cells, ranging from 3-46% of the total 
population. The fraction of cells with normal, nuclear XPF-ERCC1 ranged from 26-73%.  The 
fact that all known XPF mutations lead to mislocalization of XPF-ERCC1 into the cytoplasm, 
yet not all cells harboring mutant XPF display cytoplasmic protein suggests that cytoplasmic 
XPF-ERCC1 may be rapidly degraded. Alternatively, there may be tremendous selection 
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pressure for cells with nuclear XPF-ERCC1, consistent with the notion that that repair complex 
is essential for human life. Indeed, serial passaging of XP51RO cells over years led to a striking 
increase in the fraction of cells with nuclear XPF-ERCC1 and reduced sensitivity to the 
crosslinking agent mitomycin C (Niedernhofer, unpublished data), likely leading to 
underrepresentation of the fraction of cells with cytoplasmic XPF-ERCC1 in Figure 3-2D, 
although these were relatively early passage cells. 
3.2.3 Analysis of R153P mutation in XPF cDNA 
To further rule out the possibility that the cytoplasmic XPF-ERCC1 detected was an artifact 
generated by non-specific antibodies, XPFR153P and XPFWT were tagged with YFP and expressed 
in Xpf mutant hamster cells (UV41 or UV47) for direct detection. The expression of fusion 
proteins was confirmed by immunoblot using antibodies against human XPF and GFP (Figure 3-
3A). Immunodetection of XPF revealed numerous breakdown products of XPF, likely due to its 
overexpression, but only a single fusion protein migrating at the expected molecular mass of full 
length XPF-YFP. To determine if the fusion proteins were functional, transiently transfected 
cells were tested for their sensitivity to UV to measure NER and mitomycin C (MMC) to 
measure interstrand crosslink repair (Figure 3-3B). Wild-type XPF-YFP yielded near complete 
correction of the hypersensitivity of UV41 mutant cells to UV and MMC. By contrast, despite 
the fact that XPFR153P_YFP was expressed to the same extent as XPFWT-GFP, this protein was 
unable to correct either DNA repair defect (Figure 3-3B) as expected based on the 
hypersensitivity of the XP51RO patient cell lines (Niedernhofer et al., 2006). To determine the 
sub-cellular localization of XPFR153P, cells expressing the YFP-tagged protein was plated on 
glass coverslips and the protein detected by fluorescence microscopy (Figure 3-3C). XPFWT-YFP 
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was exclusively in the nucleus. However, XPFR153P_YFP was detected in the cytoplasm of 95% 
of the transfected cells. These results confirm that mutation of XPF leads to its mislocalization to 
the cytoplasm of cells.  
 
Figure 3-3: Characterization of XPF-YFP and XPF153-YFP in CHO cells 
A, Western blot analysis of XPF-YFP expressed in Xpf mutant cells. XPF-deficient hamster cell line, 
UV41, was transiently transfected with wild type XPF-YFP or XPF153-YFP and the fusion proteins were 
detected using an antibody against XPF or GFP. C5RO was used as positive control for the XPF blot and as a 
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negative control for the GFP blot. UV41 cells transfected with YFP alone was used as a negative control for 
XPF blot and as a positive control for GFP blot. B, Clonogenic survival of wild type (wt), XPF-deficient CHO 
cell line UV41, and UV41 transfected with wild type XPF-YFP and XPF153-YFP after UV and MMC 
treatment. Colonies were counted 7-10 days after treatment and results are plotted as mean 3 independent 
experiments. C, Subcellular localization of wild type XPF-YFP and XPF153-YFP after transient transfection in 
XPF-deficient the CHO cell line UV41 detected by fluorescence microscopy. 
3.2.4 Characterization of XPFR153P-ERCC1 activity in living cells 
Unscheduled DNA synthesis (UDS) measures the incorporation of radiolabeled nucleotides in 
nuclei of non-S phase cells by autoradiography after exposure of the cells to ultraviolet radiation 
and is a direct measure of NER (Hoeijmakers et al., 1990). The amount of UDS for patient cells 
is reported as a percent of UDS relative to that found in cells from an unaffected individual. 
Previously, UDS in cells from patient XP42RO (XPFR799W) and XP51RO (XPFR153P) was found 
to be 19% and <5%, respectively (Table 3-1).  For all of the patient cell lines with the exception 
of XP51RO UDS levels are above background. This establishes that the mutant XPF proteins, 
with the exception of XPFR153P, are catalytically active in vivo. 
To test the ability of the mutant XPF-ERCC1 protein complexes to participate in NER in 
living cells, recombinant, purified XPFR153P-ERCC1 and XPFR799W-ERCC1 (Figure 3-1) were 
micro-injected into the nuclei of XP51RO primary fibroblasts. XP51RO cells were first fused on 
slides by treatment with inactivated Sendai virus to produce homopolykaryons (multinucleate 
cells). Only homopolykaryons were injected with protein, to permit distinction of cells injected. 
The slides were irradiated with 10 J/m2 UV-C, cultured in the presence of 3H-thymidine and 
nuclear grains indicating sites of thymidine incorporation in non-S phase cells measured (Figure 
3-4). There was a significant increase in the number of grains detected in homopolykaryons 
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relative to individual cells in the same culture for all samples. Importantly, a similar level of 
UDS or NER was detected in homopolykaryons injected with XPFR153P-ERCC1 and XPFR799W-
ERCC1 as wild type XPF-ERCC1. These data demonstrate that both mutant XPF complexes are 
enzymatically active once inside the nucleus and therefore that the severe phenotype seen in 
XP51RO is likely due to the inability of XPFR153P-ERCC1 to enter the nucleus.  
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y without skin 
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100% 1X rare (Sijbers et al., 
1998) 
XP23OS 455fs ?* 45 - mild XP 45% 4X rare (Arase et al., 
1979) 

















20% 2X 33% (Sijbers et al., 
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XP2YO T567A♦ 657fs 65 + mild XP 17% 3X n.d. (Matsumura 
et al., 1998) 
AS871 R589W del 
exon3 
  severe XP with 
neurodegenerat
ion 
15% 2X 59%  
XP26BR R799W R799W   mild XP 15% not 
reported 
33%  
XP32BR R589W P379S 12 - mild XP 10% 2X 39%  
XP24BR R799W R589W 29 - severe XP with 
neurodegenerat
ion 
5% 3X 74% (Berneburg et 
al., 2000) 
XP24KY R799W 537fs 
+ 7bp 




7% 3X 45% (Matsumura 
et al., 1998) 
XP51RO R153P R153P 16 - neurodegenerat
ion severe 
progeria 
<5% 10X >33% 
 
(Niedernhofer 
et al., 2006) 
UDS unscheduled DNA synthesis 
*The patient had normal levels of XPF transcript, suggesting one allele encodes a full-length mRNA. 
♦Mutation not confirmed on genomic DNA. 
°Siblings. 
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3.2.5 Clinical correlation 
To determine if the severity of disease associated with a particular mutation in XPF could be 
predicted by the amount of XPF-ERCC1 detected in cell nuclei, the results in Figure 2D were 
compared to the clinical information about the patients from which the cells were derived (Table 
3-1).  In Table I, the cell lines were listed in order of decreasing UDS. Of note, for all patients for 
which the mutation in XPF was confirmed by sequencing genomic DNA, each is harboring one 
of four recurrent point mutations. The observations that XPF mutations are extremely rare, 
predominantly point mutations and redundant between patients are all consistent with the notion 
that XPF is essential for life.  
Patients with mild disease tend to have greater UDS. Patients XP32BR and XP26BR 
could be exceptions, but they are too young to be certain. In Figure 3-2D, the cell lines are 
clustered into those from patients in which severe disease/neurodegeneration was documented 
(right) or not yet observed (left). There is a trend towards those with severe disease to have more 
non-nuclear XPF-ERCC1, but this trend did not reach significance (p=0.06, unpaired Student’s t-
test). 
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Figure 3-4: Correction of Xpf mutant cell NER defect by micro-injection of XPF-ERCC1 
Primary fibroblasts from XFE progeroid patient XP51RO were fused to create homokaryons by 
treatment with inactivated lentivirus then plated on glass coverslips.  Homopolykaryons were injected with 
recombinant XPF-ERCC1 protein complex A, wild-type B, XPF R799W-ERCC1 C, XPF R153P-ERCC1. The 
cultures were irradiated with 10 J/m2 UV-C and 3H-thymidine was added to the culture. UV-induced 
unscheduled DNA synthesis was detected by autoradiography. Homopolykaryons are indicated with arrows.   
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3.3 DISCUSSION 
Classically, inherited mutations in a gene are associated with a single disease. However, 
mutations in several genes involved in the NER pathway can result in more than one disease.  
The most prominent example is XPD, which if mutated can cause the cancer-prone disease XP 
but also Cockayne Syndrome (CS), characterized by photosensitivity, growth retardation, 
developmental abnormalities and profound neurodegeneration, as well as trichothiodystrophy 
(TTD), which is similar to CS, but also involves the skin and nails (Taylor et al., 1997).  
Similarly, mutations in XPB can also cause XP, TTD and a combined XP-CS (Vermeulen et al., 
1994) and mutations in XPG can lead to XP or XP-CS (Nouspikel et al., 1997). Of all the genes 
whose products are required for NER, only XPB, XPD and XPG are required for the proper 
function and stability of the basal transcription factor TFIIH (Ito et al., 2007). Thus the more 
severe symptoms of CS and TTD are attributed to a combined defect in NER as well as 
transcription (de Boer et al., 2002; Kraemer et al., 2007; Takayama et al., 1996; Taylor et al., 
1997). More recently, mutations in XPF were linked to a second disease in addition XP, a 
disease of systemic accelerated aging termed XFE progeroid syndrome (Niedernhofer et al., 
2006). In this study, we investigated the underlying basis of how mutations in XPF cause 
disease. 
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3.3.1 Mutations in XPF do not ablate catalytic activity 
Since CS and TTD are attributed to defects in transcription (van Gool et al., 1997; Vermeulen et 
al., 2000), the prediction is that mutations in XPB, XPD or XPG that cause CS or TTD should 
affect basal transcription in addition to NER, whereas mutations that affect only NER cause XP. 
Indeed, mutations in the catalytic domain of XPG, for example A792V, disrupt the endonuclease 
activity of the XPG, but not its interaction with TFIIH and therefore causes classical XP 
(Clarkson, 2003). Similarly, a mutation in the helicase domain of XPD, D234N, affects NER, but 
not basal transcription and therefore leads to XP (Dubaele et al., 2003). By analogy, we 
examined the enzymatic activity of XPFR153P and XPFR799W, which cause XFE progeroid 
syndrome and XP respectively, and discovered that neither mutation ablates the catalytic activity 
of the protein (Figure 3-1). Recombinant proteins harboring either mutation are able to incise a 
stem-loop substrate in vitro, though less efficiently than the wild type protein. This demonstrates 
that these mutations in XPF do not prevent enzymatic activity of the nuclease. 
3.3.2 Stability of XPFR799W-ERCC1 and XPFR153P-ERCC1 is reduced 
Mutations in a single gene could potentially lead to distinct clinical outcomes if mutations 
differentially affect the stability of the gene product. For example, mutations affecting the 
stability of the TFIIH complex are linked with TTD but not XP (Vermeulen et al., 2000).  XPF 
levels are reduced in cells from patients with accelerated aging, carrying R153P and R799W 
mutations (Figure 3-1C), and a milder XP patient XP2YO (Niedernhofer et al., 2007), compared 
to cells from unaffected individuals. Therefore mutant XPF may be rapidly degraded. However, 
XPF levels are similar all of these XPF mutant cells lines despite significantly different levels of 
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NER (Table 3-1). Therefore, it is unlikely that the severity of the disease caused by mutations in 
XPF is dictated by the level of expression or degradation of the mutant protein. 
3.3.3 Mutations in XPF affect protein subcellular localization  
The novel and unexpected finding is that mutation in XPF leads to increased cytoplasmic 
localization of the XPF-ERCC1 nuclease complex (Figure 3-2 and 3-3) and that this aberrant 
subcellular localization is what prevents XPF-ERCC1 from participating in DNA repair (Figure 
3-4). This was demonstrated by immunofluorescence detection of the complex using multiple 
antibodies as well as by immunoblot after cellular fractionation (Figure 3-2). The results were 
confirmed by examining the subcellular localization of fluorescently tagged recombinant XPF 
(Figure 3-3). 
Several human diseases are associated with misrouting or mislocalization of proteins, 
ranging from metabolic disorders to cancer. Mislocalization of proteins may result from a 
mutated nuclear localization sequence (NLS) or nuclear export sequence (NES).  Remarkably, 
the majority of the missense mutations in XPF is at arginine residues and leads to conversion to a 
noncharged residues. So these mutations could affect a complex nuclear localization signal 
(NLS). All of the point mutations (R→P, R→W and P→S) are also predicted to alter protein 
structure and therefore may affect protein folding and/or protein:protein interactions that are 
critical for nuclear localization.  
Mislocalization of the tumor suppressors p53 (Moll et al., 1992), FOXO (Kau et al., 
2004), p27Kip1 (Min et al., 2004) and β-catenin (Rosin-Arbesfeld et al., 2003) in the cytoplasm 
rather than the nucleus, leading to a loss of protein function, are associated with multiple cancers. 
In contrast, mislocalization of NF-κB (Karin et al., 2002), BRCA1 and BARD1 (Fabbro et al., 
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2002; Karin et al., 2002) from the cytoplasm into the nucleus is also associated with a variety of 
tumors. A classic example of a disease caused by protein mislocalization is cystic fibrosis which 
is caused by retention of the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein in the endoplasmic reticulum, instead of its localizing to the cell surface (Edwards et al., 
2000; Welsh and Smith, 1993). In addition, nephrogenic diabetes inspidus, retinitis pigmentosa, 
emphysema and α1-antitrypsin deficiency liver disease are also caused by mislocalized proteins 
(Edwards et al., 2000).  
Our data add XPF to the list of proteins that when mislocalized cause disease. In the case 
of XPF, it is the absence of XPF and its binding partner ERCC1 in the nucleus, causing reduced 
repair of genomic DNA that is disease-causing, rather than toxicity of mislocalized protein. The 
data also raise the possibility of a novel mechanism by which the DNA repair capacity of a cell is 
regulated: via proteins required for nuclear localization of XPF-ERCC1. Such proteins would be 
excellent targets for small molecule inhibitors that would reduce repair and thereby tumor 
resistance to genotoxic chemotherapeutic agents. 
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3.4 MATERIALS AND METHODS 
3.4.1 Biochemical characterization of XPFR153P-ERCC1 and XPFR799W-ERCC1  
Purification of recombinant XPF–ERCC1 was performed essentially as previously reported 
(Enzlin and Scharer, 2002) from baculovirus-infected Sf9 insect cells using a His6 tag on 
ERCC1. In brief, plasmids pFastBac1-XPF and pFastBac1-ERCC1-His were used to transfect 
Sf9 insect cells, and to amplify the virus according to the manufacturer's instructions (BAC TO 
BAC system; Life Technologies). Cell extracts were prepared 65 hr after infection with an MOI 
of 5 and highly purified protein was obtained using chromatography on Ni−agarose, gel-filtration 
and heparin columns. Only XPF-ERCC1 eluting as proper heterodimer on the gel filtration 
column at ~65 ml of eluant was collected. The aggregated protein, eluting in the void volume 
(~40-50 ml), was not used in experiments.  
The endonuclease activity of wild-type and mutant XPF-ERCC1 was performed using a 
stem−loop substrate also as previously described (Enzlin and Scharer, 2002). A stem12−loop22 
oligonucleotide (GCCAGCGCTCGGT22CCGAGCGCTGGC) was 5'-32P end-labeled. Nuclease 
reactions were performed on 100 fmol of DNA substrate and 20-200 fmol of XPF-ERCC1 
protein in a total volume of 15 µl in optimized nuclease buffer (25 mM HEPES pH 8.0, 40 mM 
NaCl, 10% glycerol, 0.5 mM β-mercaptoethanol, 0.1 mg/ml bovine serum albumin and 0.4 mM 
MnCl2 or 2 mM MgCl2). The reactions were incubated at 30°C for 2 h and stopped by adding 15 
µl of 90% formamide/10 mM EDTA and heating at 95°C for 5 min. Samples were loaded onto 
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15% denaturing polyacrylamide gels and reaction products were visualized by autoradiography 
and quantified on a PhosphorImager (STORM860; Molecular Dynamics). 
In vitro NER reactions were performed as described previously (Shivji et al., 1999; 
Tsodikov et al., 2005). In brief, a plasmid containing a single 1,3-intrastrand d(GpTpG)-cisplatin 
adduct was incubated with 500 µg of whole cell extracts prepared from XPF-deficient XP2YO 
cells complemented with recombinant XPF-ERCC1, XPFR153P-ERCC1 or XPFR799W-ERCC1. 
The fragments excised during NER were labeled by annealing them to a complementary 
oligonucleotide with a four guanosine 5’ overhang and filling in the overhang with Sequenase 
and [α-32P]-dCTP. Products were resolved on a 14% sequencing gel and detected by 
autoradiography. 
3.4.2 Cell lines and culturing  
Human fibroblasts immortalized with hTert were cultured in Ham's F10 with 10% fetal calf 
serum and antibiotics and incubated at 3% oxygen as described previously (Niedernhofer et al., 
2006). Cell lines included those derived from a normal individual (C5RO) (Poot et al., 1987), the 
parent of a patient, heterozygous for a mutation in XPF (Sijbers et al., 1998), XP-F patients 
(XP42RO) (Sijbers et al., 1998), XP23OS (Arase et al., 1979), XP24KY (Matsumura et al., 
1998), XP7NE (Berneburg et al., 2000), XP32BR, XP26BR, XP24BR (Berneburg et al., 2000), 
and XP62RO, and a patient with XFE progeroid syndrome caused by a mutation in XPF 
(XP51RO) (Niedernhofer et al., 2006)  
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3.4.3 Immunodetection of XPF in patient cells 
Cells were trypsinized, washed twice with PBS and lysed with 1 ml NETT buffer (100 mM 
NaCl, 50 mM Tris base pH 7.5, 5 mM EDTA pH 8.0, 0.5% Triton X-100) containing 
Complete™ mini protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche 
Molecular Biochemicals). Then the lysates were freeze-thawed twice in liquid nitrogen to disrupt 
nuclear membranes. From each sample, 50 µg of protein was resolved on 10% SDS-PAGE gels 
after boiling for 10 min in the presence of loading buffer. XPF was detected using a human XPF 
monoclonal antibody (clone 219; Neomarker, Fremont, CA) at a dilution of 1:1000.  
3.4.4 Differential immunofluorescence of fibroblasts isolated from patients with 
mutations in XPF  
Cultures of primary human fibroblasts from patients with mutations in XPF or a normal 
individual were grown in the presence of different size beads (2 µm or 0.8 µm; Sigma).  After 24 
hr the cultures were trypsinized and washed extensively with phosphate-buffered saline to 
remove any extracellular beads.  The cells were then mixed in various combinations and co-
plated on glass coverslips to provide internal controls of normal XPF-ERCC1 protein levels 
(Vermeulen et al., 2000).  After 16 hr, the cells were fixed with 2% paraformaldehyde in sodium 
phosphate buffer, pH 7.4, for 15 min then permeabilized with 0.1% Triton X-100 in PBS.  The 
samples were immunostained with polyclonal anti-ERCC1 (1:2000; (van Vuuren et al., 1995)) or 
polyclonal anti-XPF (1:1000; (Sijbers et al., 1996a)) followed by goat anti-rabbit ALEXA 488 
(1:500; Molecular Probes).  Samples were stained with Dapi to identify nuclei and examined by 
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phase contrast microscopy to identify the genotype of the cells according to their bead content 
and by fluorescence microscopy for immunodetection of repair proteins. 
3.4.5 Cell fractionation 
Cells were fractionated into nuclear and cytosolic fractions as described (Kapetanaki et al., 
2006), with minor modification. In brief, cells were trypsinized, pelleted and washed twice with 
PBS. The pellet was vortexed at maximum speed for 15 sec with 200 µl of CERI reagent from 
the Pierce NE-PER fractionation kit (Pierce Biotech) with Complete™ mini protease inhibitor 
cocktail, then incubated on ice for 10 min. This was followed by addition of 11 µl of CERII, 
vortexing for 5 sec and incubation on ice for 1 min. The mixture was spun at 13,000 rpm for 5 
min and the supernatant collected as the cytosolic fraction. The nuclei in the pellet were 
suspended in extraction buffer (15 mM Tris-HCl pH 7.3, 1 mM EDTA, 0.4 M NaCl, 1 mM 
MgCl2, 10% glycerol, 10 mM β -mercaptoethanol and Complete™ mini protease inhibitor 
cocktail), mixed for 1 hr at 4°C and spun down at 13,000 rpm for 10 min. The supernatant was 
collected as the soluble nuclear fraction.  
3.4.6 Subcellular localization of XPF-YFP in Chinese hamster Ovary (CHO) cells 
XPF cDNA was cloned into pYFP-N1 (BD Biosciences Clontech, Palo Alto, CA) such that YFP 
was expressed as fusion protein at the C-terminus of XPF. This construct, pXPF-YFP-N1, was 
then used to create XPFR153P-YFP by QuickChangeR Site-Directed Mutagenesis Kit (Stratagene, 
Cedar Creek, TX) according to the manufacturer’s instructions. The wild type and mutant 
constructs were transfected in XPF-deficient CHO cell lines UV41 or UV47 using 
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lipofectamineTM 2000 (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. 
Cells expressing YFP were flow sorted using Dako Cytomation MoFLo high-speed cell sorter 
(Dako North America, Carpinteria, CA) 24-48 hrs after transfection.  
To study the subcellular localization of XPF, YFP-positive CHO cells were plated on 
glass coverslips and grown to 95% confluency. The next day, the samples were fixed with 2% 
paraformaldehyde in sodium phosphate buffer, pH 7.4, for 15 min. The cells were permeabilized 
with 0.1% Triton X-100 in phosphate-buffered and nuclei were stained with Dapi-vector shield 
(Vector Laboratories, Inc. Burlingame, CA). XPF-YFP was visualized using an Olympus BX51 
fluorescent 4 microscope at 60-100X magnification. 
3.4.7 Clonogenic survival assays of wild type and mutant CHO cells  
Wild type (AA8), XPF-deficient (UV41), XPF-YFP and XPFR153P-YFP cells were seeded in 6 
cm dishes in triplicate at 103-104 cells per plate, depending on the dose of genotoxin. After 16 hr, 
the cells were irradiated with UV-C or exposed to mitomycin C (MMC).  After approximately 
one week, the cultures were fixed and stained with 50% methanol, 7% acetic acid and 0.1% 
Coomassie blue. Colonies, consisting of at least 10 cells, were counted using a Nikon SMZ 2B 
15 stereomicroscope microscope with 10X eyepiece. The data were plotted as the number of 
colonies that grew on the treated plates relative to untreated plates ± the standard error of the 
mean for 2-3 independent experiments.  
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3.4.8 Immunoblotting of XPF in Wt and mutant CHO cells 
Whole cell extracts were prepared from C5RO and UV41 cells transfected with vectors 
expressing YFP, XPF-YFP or XPFR153P-YFP. Proteins were separated by SDS PAGE using a 
10% gel. XPF was detected using a human XPF monoclonal antibody (clone 219; Neomarker, 
Fremont, CA) at a dilution of 1:1000. YFP was detected using a GFP monoclonal antibody 
(Clones 7.1 and 13.1; Roche, Indianapolis, IN) at a dilution of 1:1000. 
3.4.9 Correction of XPF mutant cell UV sensitivity by micro-injection of recombinant 
XPF-ERCC1   
Microinjection of purified proteins was performed as previously described (de Jonge et al., 1983; 
Weeda et al., 1990).  Briefly, primary human fibroblasts from XP51RO were fused by treating 
cultures with inactivated Sendai virus and then plated on glass coverslips.  Subsequently, 
purified, recombinant XPF-ERCC1 protein complex (wild type or containing the R799W or 
R153P mutation in XPF) was injected into the nuclei of homopolykaryons. The cultures were 
irradiated with 10 J/m2 UV-C and pulse labeled for 3 hrs with 3H-thymidine. Unscheduled DNA 
synthesis (UDS) was detected by autoradiography. 
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4.0  IMMUNODETECTION OF DNA REPAIR ENDONUCLEASE ERCC1-XPF IN 
HUMAN TISSUE 
This chapter was published in Cancer Research: 
Bhagwat, N.R., Roginskaya, V.Y., Acquafondata, M.B., Dhir, R., Wood, R.D., and 
Niedernhofer, L.J. (2009b). Immunodetection of DNA repair endonuclease ERCC1-XPF in 
human tissue. Cancer research 69, 6831-6838. 
4.1 INTRODUCTION 
It is important to identify molecular markers that help guide cancer treatment decisions to 
improve patient survival and quality of life in advanced stage disease. Non-small cell lung 
carcinoma (NSCLC), accounting for ~85% of all lung cancers in the United States, is a prime 
example. The overall five-year survival rate is only 17%, largely because NSCLC is rarely 
detected prior to dissemination and current methods of screening are ineffective (Patz et al., 
2000; Ries LAG, 2008). Platinum-based chemotherapy can improve survival when used as 
adjuvant therapy after surgical resection of NSCLC (Arriagada et al., 2004; Winton et al., 2005). 
For patients with stage IIIB or IV disease, platinum-based combination chemotherapy is the first 
line of treatment (Bulzebruck et al., 1992; Bunn and Kelly, 1998). However, this is effective in 
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only a subset of patients. Prediction of which patients are mostly likely to respond to platinum-
based chemotherapy is therefore imperative. 
Cisplatin [cis-diamminedichloroplatinum(II)] and related platinum-based drugs inhibit 
cell proliferation because they cause DNA damage, including adducts on single bases, intrastrand 
crosslinks between two bases, and interstrand crosslinks (ICLs) between DNA strands (Eastman, 
1987). The monoadducts and intrastrand crosslinks are repaired by nucleotide excision repair 
(NER), a DNA repair mechanism that excises helix-distorting lesions affecting one DNA strand. 
ICLs are repaired by mechanisms that remain poorly defined, but involve proteins from multiple 
DNA repair pathways including homologous recombination (De Silva et al., 2000), Fanconi 
anemia (Friedberg, 2006; Niedernhofer et al., 2005), translesion polymerases and NER (Collins, 
1993). ERCC1-XPF is a structure-specific nuclease, that acts both in NER (Sijbers et al., 1996a) 
and the repair of ICLs (De Silva et al., 2000). Thus, ERCC1-XPF is uniquely important for 
protection against the cytotoxicity caused by cisplatin-induced DNA damage. If ERCC1-XPF 
levels vary between tumors, it would be an attractive target for use as a predictor of the efficacy 
of platinum-based chemotherapy.  
XPF harbors the catalytic domain in the heterodimeric nuclease, (Enzlin and Scharer, 
2002) and ERCC1 is required for DNA binding (Tsodikov et al., 2005). The levels of ERCC1 
are reduced in XPF-deficient mammalian cells and vice versa, suggesting that the proteins 
stabilize one another in vivo (Biggerstaff et al., 1993). Due to the obligate nature of this 
partnership, it follows that cellular levels of the two proteins should be closely correlated and 
that either could potentially be a good biomarker of the response to platinum-based therapy. 
There has been increasing interest in measuring the levels of ERCC1 in NSCLC 
specimens by immunohistochemistry (IHC) (Hwang et al., 2008; Lee et al., 2008; Olaussen et 
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al., 2006; Zheng et al., 2007). ERCC1 expression, as measured by IHC, was reported to correlate 
with poor response to cisplatin chemotherapy and significantly decreased survival (Olaussen et 
al., 2006). On the other hand, it has also been reported that increased ERCC1 in tumours was 
associated with longer survival after surgical treatment of NSCLC (Lee et al., 2008; Zheng et al., 
2007). Unfortunately, the antibody (8F1) used in almost all studies is not specific for ERCC1 
(Niedernhofer et al., 2007). It recognizes human ERCC1, but also a second major nuclear 
antigen of unknown identity, and the antibody is unable to discriminate between cells expressing 
ERCC1-XPF and cells that do not (Niedernhofer et al., 2007).  
To determine if ERCC1-XPF is a biomarker for prognosis and making therapeutic 
decisions in NSCLC or other types of cancer, the specificity of relevant antibodies must be 
critically evaluated. Here we examine a collection of antibodies raised against each subunit of 
the nuclease for their ability to specifically detect their respective antigens in several 
applications. This not only provides reliable tools for the detection of ERCC1 and XPF in 
clinical specimens, but also illustrates a strategy for the validation of other antibodies against 
other potential biomarkers that could stratify patients according to cancer risk, response to 
therapy and prognosis. 
  86 
4.2 MATERIAL AND METHODS 
4.2.1 Cell lines, recombinant proteins and whole cell extract preparation 
Primary human fibroblast cell lines C5RO (normal), XP51RO (XPF mutant) (Niedernhofer et 
al., 2006), 165TOR (ERCC1 mutant) (Jaspers et al., 2007) and XP25RO (XPA mutant) were 
cultured in Ham’s F-10 with 10% fetal bovine serum (FBS), antibiotics and non-essential amino 
acids. Transformed human fibroblasts XP2YO (XP-F) (Yagi et al., 1991) were cultured in RPMI 
with 10% FBS, antibiotics and non-essential amino acids. CHO cell lines AA8 (wild-type) 
(Thompson et al., 1980), UV47 (Xpf mutant) and 43-3B (Ercc1 mutant) (Wood and Burki, 1982) 
were cultured in D-MEM with 10% FBS, antibiotics and non-essential amino acids. Mouse 
embryonic stem (ES) cell lines IB10 (wild-type) and clone 49 (Ercc1-/-) (Niedernhofer et al., 
2001) were cultured in a 1:1 mixture of DMEM and Buffalo rat liver (BRL) cell conditioned 
media with 10% FBS, antibiotics, non-essential amino acids, 0.1 mM 2-mercaptoethanol and 
leukemic inhibitory factor (1000 units/ml, Gibco).  
Recombinant XPF with an N-terminal His tag and ERCC1 with a C-terminal His tag 
were expressed from a dicistronic construct in E. coli and purified, as previously described 
(Kuraoka et al., 2000). For preparation of whole cell extracts (WCEs), cells were grown to 80-
90% confluence in 10 cm dishes or 75 cm2 flasks, trypsinized and washed with PBS, and then 
lysed at 4ºC for 30 min with NP-40 lysis buffer (1% NP-40, 10% Glycerol, 20 mM Tris, pH 7.4, 
137 mM NaCl, 2 mM Na3V04 and protease inhibitor cocktail set III (Calbiochem). 
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4.2.2 Immunoblotting and immunoprecipitation 
For immunoblotting, 50 µ g of total protein from each WCE and 20 ng of recombinant HIS-
tagged ERCC1 and XPF were boiled in 4X loading buffer (0.25 M Tris-HCl, pH 8.5, 8% SDS, 
1.6 mM EDTA, 0.1 M DTT, 0.04% bromophenol blue and 40% glycerol), separated by SDS-
PAGE  (10% polyacrylamide gel), and transferred to a nitrocellulose membrane. Anti-ERCC1 
and anti-XPF antibodies (listed in Table 4-1) were tested for their ability to specifically detect 
the respective proteins.  
For immunoprecipitation, WCEs of C5RO cells were pre-cleared for 30 min by 
incubation with protein A+G agarose beads (Calbiochem) and incubated at 4ºC with 10 µ l of 
each of the primary antibodies and 25 µl protein A+G beads with continuous mixing for 12 hr. 
The beads were collected by centrifugation at maximum speed (15 min), washed three times 
each with the NP-40 lysis buffer and PBS, boiled for 10 min in protein loading buffer, and eluted 
proteins separated by SDS-PAGE. Immunoprecipitated XPF was detected with anti-XPF 
antibody (Ab-1, Neomarkers, 1:1000) and AP conjugated goat anti-mouse secondary antibody 
(1:7500, Promega). 
4.2.3 Immunofluorescence and UV-C-induced local damage 
C5RO and XP2YO cells were plated at 75-80% confluence and labeled with 0.6 µm and 3 µm 
diameter latex beads (Sigma-Aldrich) respectively, as described (Botta et al., 2002; Vermeulen 
et al., 2000). After 24 hr, cells were washed three times with PBS, trypsinized and co-plated on 
coverslips. Twelve hr later, the cells were fixed with 2% paraformaldehyde (ICN Biomedicals) at 
37ºC for 15 min. Triton-X-100 (0.2% in PBS) was used to permeabilize the cells and 5% BSA in 
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PBS was used for blocking. Primary antibodies were used as described in Supplemental Table 2. 
Goat anti-mouse IgG (1:1000), chicken anti-rabbit IgG (1:1000), goat anti-mouse IgG2b (1:500) 
or goat anti-mouse IgG1 (1:500) secondary antibodies conjugated either with Alexa fluor 488 or 
Alexa fluor 594 (Invitrogen) were used for visualization. 
For co-localization of ERCC1-XPF with UVC radiation-induced cyclobutane pyrimidine 
dimers (CPD), experiments were performed as described (Mone et al., 2001; Volker et al., 2001) 
with minor modifications. C5RO cells grown on glass coverslips were irradiated with 60 J/m2 
UV through Isopore™ membrane filters (Millipore) with 8 µ m pores to induce subnuclear 
domains of DNA damage. The cultures were then incubated in medium for 45 min to allow 
initiation of DNA repair, and then fixed with 2% paraformaldehyde with 0.15% Triton-X-100 for 
15 min on ice. Samples were blocked with 5% BSA in PBS for 20 min at RT and incubated with 
anti-ERCC1 or anti-XPF antibodies at the same dilution as for immunofluorescence (Table 4-2) 
for 90 min at RT. Secondary antibodies were used as described above. This was followed by 
fixation with 2% paraformaldehyde for 10 min, denaturation with 2N HCl for 5 sec and blocking 
with 5% BSA in PBS for 20 min, all at RT. Cells were stained secondarily for CPDs using 
mouse anti-thymine dimer antibody (1:200, Kamiya Biomedical) for 90 min at RT and either 
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Table 4-1: Results of the antibody screen 
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4.2.4 Immunohistochemistry 
C5RO, HeLa, XP42RO, XP51RO, 165TOR and XP2YO cells were grown to 75-80% 
confluence, fixed at room temperature with 10% neutral-buffered formalin for 15 min, and then 
collected by scraping. Cells were stored in neutral-buffered formalin at 4ºC for at least 3 hr, then 
pelleted by centrifugation (1,200 rpm, 5 min) and washed twice with PBS. Cells were 
resuspended in 500 µ l of 80% ethanol, transferred to Eppendorf tubes containing 300 µ l of 
solidified 1% low melting point agarose in PBS, and re-pelleted. The ethanol was aspirated and 
the bottoms of the tubes cut off. The agarose plugs containing the cells were pushed and molded 
into the caps of Eppendorf tubes and snap frozen on dry ice. The solidified pellets were extruded 
from the caps and paraffin embedded according to standard methods for tissue.  
For immunohistochemical staining of the cell plug and paraffin embedded tissue sections, 
antigen retrieval was carried out at pH 6 (Dako Target retrieval solution, Dako) at 95°C for 20 
min. Samples were blocked with 20% swine serum for 30 min and then incubated with either 
FL297 (anti-ERCC1, rabbit polyclonal, 1:250) or 3F2 (anti-XPF, mouse monoclonal, 1:1000) for 
60 min at room temperature. Primary antibody signal was then detected using biotinylated anti-
rabbit or anti-mouse secondary antibody for 30 min and DAB+ for 5 min at room temperature 
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Table 4-2: Optimal antibody concentrations for immunoblots and immunofluorescence 
Dilution  
 
Antibody Immunoblot Immunofluorescence  
FL297 1:1000 1:200 
D-10 1:100 1:100 
3H11 1:500 - 
8F1 1:100 - 
RW018 1:1500 - 
RW017 1:1500 - 
Ab-1 1:100 1:200 
4H4 1:500 1:400 
3F2 1:500 1:100 
9A2 1:10000 - 
RA-1 1:5000 - 
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4.3 RESULTS 
A panel of antibodies against human ERCC1 and XPF, including commercially available 
reagents and those from our laboratory (Table 4-1), were tested for their specificity in 
immunoblotting, immunoprecipitation, immunofluorescence and IHC.  
4.3.1 Immunoblotting and Immunoprecipitation 
Antibodies were first screened for their specificity for ERCC1 or XPF by immunoblotting. 
Normal and ERCC1-XPF deficient human fibroblasts were lysed and immunoblotted along with 
recombinant His-tagged ERCC1 and XPF proteins (Figure 4-1A). Antibodies were categorized 
as specific for their target protein if they: 1) detected a band of the appropriate molecular weight 
(~116 kDa for XPF and 37 kDa for ERCC1) in normal cells (C5RO) and in XPA mutant cells 
(XP25RO), 2) detected the recombinant protein (slightly retarded in its migration due to the HIS-
tag), 3) showed significantly reduced or no signal in ERCC1 (165TOR) and XPF (XP2YO and 
XP51RO) mutant cell lines, and 4) did not detect additional bands of the incorrect molecular 
weight in both normal and mutant cells (results summarized in Table 4-1).  All of the antibodies 
screened were specific for ERCC1 or XPF on immunoblotting (e.g., 3H11 and D-10 for ERCC1; 
4H4 and 3F2 for XPF in Figure 4-1A) except for 8F1, which detected ERCC1 and an additional, 
spurious band of approximately 45 kDa. The spurious band is of equal intensity in normal and 
ERCC1-XPF deficient cells (Figure 4-1A, bottom, left panel and (Niedernhofer et al., 2007)). 
Importantly, the spurious band picked-up by 8F1 is detected in extracts from fibroblast cell lines, 
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but not HeLa cell extracts (Figure 4-1B, indicated with a “?”), which were used previously as a 
negative control for immunodetection of ERCC1 (Olaussen et al., 2007). All of the antibodies 
also detected degradation products of XPF or ERCC1 in cell lines with abundant ERCC1-XPF 
expression (Figure 4-1 A-C, bands marked by “*”). The optimal dilution of each antibody for 
immunoblotting was determined (Table 4-2).  
 
Figure 4-1: Immunodetection of ERCC1-XPF in whole cell extracts 
A, Examples of how each of the test antibodies was screened for specificity for ERCC1 or XPF by 
immunoblot. WCEs were prepared from normal (C5RO), XPA mutant (XP25RO), XPF mutants (XP51RO 
and XP2YO) or ERCC1 mutant (165TOR) human fibroblasts. Proteins were separated by SDS-PAGE and 
identified on the blot by loading recombinant His-tagged ERCC1-XPF. Blots were immunostained with each 
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of the test antibodies (e.g., anti-XPF: 4H4 and 3F2, and anti-ERCC1: 3H11, D-10 and 8F1). Tubulin was used 
as a loading control. An asterisk (*) is used to denote degradation products of ERCC1 or XPF detected by all 
antibodies and a question mark (?) is used to denote an unidentified spurious band detected only by the 8F1 
antibody.  B, 8F1, but not D-10 or 3H11, detects a band that migrates more slowly than ERCC1 (denoted ?). 
This antigen is found in fibroblasts (C5RO and XP2YO), but not HeLa cells. C, Two examples of screening 
the test antibodies for their ability to detect ERCC1 or XPF in mouse or hamster cell extracts. Lysates were 
prepared from wild-type (IB10) and Ercc1-/- mouse embryonic stem cells (clone 49) as well as wild-type 
(AA8), Ercc1 mutant (43-3B) and Xpf mutant (UV47) Chinese hamster ovary cells. These were run on SDS-
PAGE along with recombinant His-tagged ERCC1-XPF. Blots were immunostained with each of the test 
antibodies (e.g., anti-XPF RA-1 and anti-ERCC1 D-10). Tubulin was used as a loading control. D, 
Immunoprecipitation of ERCC1-XPF from WCEs from normal human fibroblasts with each of the test 
antibodies. Precipitates were separated by SDS-PAGE, blotted and immunostained with antibody Ab-1 to 
detect XPF protein. 
 
To further test the utility of these antibodies, WCE from wild-type and ERCC1-XPF 
deficient mouse embryonic stem cells (IB10 and clone 49, respectively) and Chinese hamster 
ovary cells (AA8, CHO43-3B [Ercc1 mutant] and UV47 [Xpf mutant]) were also immunoblotted 
(Figure 4-1C). In general, cross-reactivity for mouse and hamster proteins was poor (Table 4-1). 
The only commercially available antibody that detected rodent ERCC1 was D-10 (Figure 4-1C).  
 Each of the ERCC1 and XPF antibodies were screened for their ability to 
immunoprecipitate their respective antigen from WCEs of normal cells (Figure 4-1D). The 
precipitates were all probed for XPF using antibody Ab-1. XPF was detected in all samples 
precipitated with antibodies against XPF, as well as antibodies against its obligate binding 
partner ERCC1, as expected (Niedernhofer et al., 2007). Immunoblotting for XPF showed that 
all antibodies tested were able to immunoprecipitate the ERCC1-XPF nuclease, indicating that 
each is appropriate for this application (Table 4-1). 
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4.3.2 Immunofluorescence 
 
Figure 4-2: Immunofluorescence detection of ERCC1-XPF in cells 
The cytoplasm of normal (C5RO) and ERCC1-XPF deficient XPF mutant human fibroblasts 
(XP2YO) was labeled with large and small latex beads, respectively. Then the cells were co-cultured on glass 
coverslips, fixed and stained. A, Brightfield images reveal both cell types in a single field. The nuclei are 
stained with DAPI. B, Immunostaining with antibody FL297 against ERCC1 distinguishes between the 
normal and ERCC1-XPF deficient cells. Nuclei of C5RO, but not XP2YO cells stain positively (red, Alexa-
594). C, Co-immunostaining with each of the test antibodies (3F2, D-10, 4H4 and 8F1; secondary antibody 
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Alexa 488, in green) reveals which are specific for ERCC1-XPF. Only those nuclei that stain positively with 
FL-297 (red nuclei in B) should show green signal. 
Antibodies that recognize denatured protein in immunoblots do not always detect their antigen in 
cells or tissues fixed with formaldehyde. Thus, each of the ERCC1 and XPF antibodies were 
screened for their ability to detect their respective antigen by immunofluorescence (IF) and 
immunohistochemistry (IHC). For IF, normal (C5RO) and XPF mutant human fibroblasts 
(XP2YO) were labeled with large (3 µm) and small (0.6 µm) latex beads, respectively, then co-
cultured on glass coverslips to create a sample with an internal negative control (XP2YO cells). 
The coverslips were simultaneously immunostained with two antibodies (Figure 4-2): the test 
antibody against ERCC1 or XPF, and FL297 an antibody against ERCC1, which we previously 
established specifically recognizes ERCC1-XPF positive cells in immunofluorescence 
(Niedernhofer et al., 2007). For the test antibody to be appropriate for IF application, it must 
stain the nuclei of normal cells only (those with large beads) and the same nuclei as FL297. Anti-
XPF antibodies Ab-1, 4H4 and 3F2 and anti-ERCC1 antibody D-10 showed nuclear staining in 
normal cells (C5RO) and no staining in XPF mutant cells (XP2YO). Antibody 8F1 stained the 
nuclei of both cell types equally and therefore was unable to distinguish between normal and 
ERCC1-XPF deficient cells (Figure 4-2, bottom panels and (Niedernhofer et al., 2007)). These 
data indicate that there are several commercially available antibodies (ERCC1: FL297 and D-10; 
XPF: Ab-1) appropriate for detecting ERCC1-XPF in human cells. Potential applications include 
fine needle aspirates and tumour biopsies. 
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4.3.3 UV-C induced local damage 
When cells are irradiated with UV-C through a polypropylene micropore filter, DNA damage is 
induced in regions of the nucleus corresponding to the filter pores (Volker et al., 2001). The sites 
of DNA damage can be identified with an antibody against UV radiation-induced 
cyclopyrimidine dimers (CPD) (Volker et al., 2001). ERCC1-XPF localizes to these sites of 
damage during NER and thus co-localizes with CPDs by immunofluorescence (Volker et al., 
2001). Co-immunostaining of UV-C irradiated fibroblasts with anti-CPD antibody and test 
antibodies against ERCC1 or XPF revealed that the antibodies which discriminated between 
normal and ERCC1-XPF-deficient cells in IF also detected functional ERCC1-XPF in this local 
damage assay (Figure 4-3). Antibody 8F1, which was unable to discriminate between normal and 
ERCC1-XPF deficient cells in IF, did not yield a signal that co-localized with CPDs (Figure 4-3, 
bottom row). These results reinforce the IF data and indicate that several commercially available 
antibodies can be used to specifically detect ERCC1-XPF in fixed cells. 
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Figure 4-3: Immunofluorescence detection of ERCC1-XPF at sites of UV-C induced DNA damage 
C5RO fibroblasts were irradiated with UV-C through a filter to induce sub-nuclear domains of DNA 
damage. The cells were stained with A, DAPI to identify the nuclei; B, anti-CPD to identify the sites of DNA 
damage and C, each of the test antibodies against ERCC1 or XPF. The merged images D, reveal which 
antibodies give a signal that co-localizes with UV-induced DNA damage, indicating their specificity for 
ERCC1-XPF DNA repair endonuclease. 
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4.3.4 Immunohistochemistry 
 
Figure 4-4: Immunohistochemical detection of ERCC1-XPF 
Normal or ERCC1-XPF deficient human fibroblasts (XP2YO) were fixed in paraformaldehyde, 
pelleted in agarose, paraffin embedded, sectioned and stained as positive and negative controls, respectively, 
for IHC with antibodies against XPF (3F2 and 4H4) and ERCC1 (8F1). Notably, 8F1 was unable to 
discriminate between the normal and ERCC1-XPF deficient fibroblasts. 
The most commonly used approach for measuring protein in tumors in clinical studies is IHC. 
However, for many essential proteins that are of interest as potential biomarkers in cancer 
prognosis, such as ERCC1 and XPF, true negative controls are not available. To circumvent this 
problem, we created paraffin-embedded blocks of normal and ERCC1-XPF deficient cell pellets 
for use as positive and negative controls to screen the test antibodies for their specificity in IHC. 
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Normal and XPF mutant human fibroblasts were fixed in paraformaldehyde, pelleted in agarose, 
embedded in paraffin, sectioned and immunostained, according to the method used for solid 
tumors. Antibody 3F2, against XPF, stained the nuclei of paraffin-embedded normal but not 
ERCC1-XPF deficient cells by IHC (Figure 4-4, first row). Similarly, antibody 4H4 against XPF 
(Figure 4-4, second row) was able to discriminate between normal and ERCC1-XPF deficient 
cells, indicating that both of these antibodies are appropriate for detection of XPF by IHC (Table 
4-1). In contrast, antibody 8F1 against ERCC1 stained the nuclei of normal and ERCC1-XPF 
deficient cells equally (Figure 4-4, third row), demonstrating its inability to discriminate between 
ERCC1 positive and negative specimens by IHC, as previously observed for other applications 
(Niedernhofer et al., 2007).  Like 8F1, the other test antibodies were unable to discriminate 
between normal and ERCC1-XPF deficient cells by IHC (data not shown), with the exception of 
FL297.  Antibody FL297 against ERCC1 was tested on six cell lines: two ERCC1-XPF 
proficient (C5RO and HeLa) and four ERCC1-XPF deficient (XP2YO, XP42RO, XP51RO and 
165TOR). FL297 stained nuclei of both repair proficient cell lines (Figure 4-5, C5RO and 
HeLa). All ERCC1-XPF deficient cells (Figure 4-5, XP2YO, XP42RO, XP51RO and 165TOR) 
did not have nuclear staining, although there was a variable level of cytoplasmic staining in all 
cell lines. ERCC1-XPF functions exclusively as a nuclear complex. Thus the absence of nuclear 
staining indicates a negative result on IHC, as expected for these ERCC1-XPF deficient cell 
lines. HeLa cells showed a more intense nuclear staining than C5RO cells. This correlates with 
the relative expression of ERCC1 in these cell lines, indicating that FL297 can distinguish 
between different levels of ERCC1 on IHC. Therefore FL297 (anti-ERCC1), 4H4 (anti-XPF) and 
3F2 (anti-XPF) are the only antibodies against ERCC1-XPF demonstrated to specifically detect 
this DNA repair nuclease by IHC. 
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Figure 4-5: Immunohistochemical detection of ERCC1 by antibody FL297 
Six human cell lines were paraffin-embedded, sectioned and stained with FL297. Two were ERCC1-
XPF proficient: C5RO and HeLa, and four were ERCC1-XPF deficient: XP2YO, XP42RO, XP51RO and 
165TOR. 
Lung tumor sections stained with antibody 3F2 display highly variable nuclear staining in 
different NSCLC samples (Figure 4-6A), suggesting that expression of XPF may vary in tumors. 
Sections from the same NSCLC tumor were immunostained with FL297 (anti-ERCC1) and 3F2 
(anti-XPF) to determine if both proteins are detected in the same cells as expected (Figure 4-6B). 
Both antibodies stained the same cell types with approximately the same intensity, confirming 
that ERCC1-XPF are co-expressed and both FL297 and 3F2 antibodies are appropriate for 
immunodetection of this repair complex in clinical specimens.  
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Figure 4-6: Immunohistochemical staining of lung tumors for ERCC1-XPF 
A, Lung tumor sections were immunostained with 3F2. Representative sections have been arranged 
in increasing order of staining intensity (i-vi) showing the range of staining variability. B, Cross-sections of 
the same tumor stained alternately with FL297 (anti-ERCC1) and 3F2 (ant-XPF) showing similarities in 
staining patterns. 
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4.4 DISCUSSION  
For several types of common cancers, e.g., lung cancer, patient survival rates have not improved 
in the last decade (Jemal et al., 2008). Response to therapy is highly variable, and in some cases, 
e.g., ovarian cancer, does not improve overall survival (Armstrong, 2002; Jemal et al., 2008; 
McGuire et al., 2002). This is particularly true for platinum-based therapies to which patients 
frequently become refractory (Modesitt and Jazaeri, 2007). Therefore, a major goal in oncology 
is to define biomarkers that can stratify cancer patients according to their likelihood of 
responding to chemotherapy. A highly active current focus of this effort is to measure expression 
of ERCC1 in tumors as a potential biomarker of DNA repair and therefore, resistance to 
genotoxic therapeutic agents (Rosell et al., 2007; Simon et al., 2007; Vilmar and Sorensen, 
2008). To infer conclusions about the mechanism of therapy failure, it is imperative to rigorously 
standardize methods to accurately measure biomarker expression. 
Immunohistochemistry (IHC) is an extremely valuable method for measuring tumor 
biomarkers. Unlike other immunological methods, IHC is applied to fixed specimens, which are 
the most abundantly available from surgical resections of tumors, allowing the large-scale 
screens necessary to validate the biological significance of novel biomarkers. Small amounts of 
tumor tissue, such as those obtained by needle biopsy, are sufficient for a semi-quantitative 
measurement of the antigen of interest. IHC is therefore used in decisions regarding diagnosis, 
prognosis and therapy of malignancies. However, there are multiple variables in the processing 
of samples in IHC and data analysis that need to be addressed prior to the widespread use of IHC 
as a quantitative immunoassay (Taylor and Levenson, 2006). The staining intensity is affected 
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significantly by the choice of fixative, the time of fixation (Grube, 2004), the extent of 
deparaffinization (Taylor, 1992), thickness of the tissue section (Grube, 2004),  the antigen 
retrieval technique (Shi et al., 1995), sensitivity and specificity of antibodies, and inter-observer 
inconsistencies in sample analysis (Taylor and Levenson, 2006). Furthermore, scoring of 
samples as positive or negative for a particular biomarker can be based on a subjective scale of 
staining intensity or percent of positively staining cells. Therefore, the importance of validating 
and standardizing every IHC protocol used in clinical trials cannot be overstated. In this 
manuscript we have critically analyzed the reagents available for measuring ERCC1 expression 
in tissue samples and developed a standardized method for ERCC1 IHC that could be applied to 
tumors. 
In order to develop an IHC protocol, the first step is to identify an antibody that is 
specific for the target antigen. This is accomplished by immunoblotting using protein extracts 
from human cells or tissue and demonstrating that the antibody detects a single band of the 
appropriate molecular weight (Holmseth et al., 2006; Pradidarcheep et al., 2008). It is imperative 
to include positive and negative controls in which the antigen is known to be expressed or 
depleted (either genetically or by shRNA), respectively (Figure 4-1). Another excellent positive 
control is recombinant tagged protein included as a molecular weight control on immunoblot or 
overexpressed in a cell line (Figure 4-1). Of eleven screened antibodies that detect ERCC1-XPF, 
ten were specific for the repair complex (Table 4-1). 
The second step in developing an IHC protocol is to validate that an antibody retains its 
specificity for an antigen in fixed samples (Holmseth et al., 2006). This can be accomplished 
directly in tissue samples only if negative controls (tissues in which the antigen is not expressed) 
are available. For many of the tumor biomarkers this is not feasible because the antigens of 
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interest are key regulators of cell cycle control and genome maintenance, and thus are 
ubiquitously expressed. Alternatively, the specificity of an antibody to detect a biomarker in 
fixed material can be validated using positive and negative control cell lines processed according 
to the IHC protocol (Figure 4-4) (Holmseth et al., 2006; Rhodes et al., 2002). In our 
experiments, normal human fibroblasts (C5RO) were used as a positive control and XP-F patient 
fibroblasts (XP2YO), deficient in ERCC1-XPF, were used as a negative control due to the 
absence of human tissue samples missing this protein (Figure 4-4). Such internal controls must 
be included in every IHC analysis (Grube, 2004; Pradidarcheep et al., 2008) (Leong, 2004). One 
important step in validating proper controls is establishing that the antigen staining has a proper 
subcellular localization, for example, ERCC1-XPF is a nuclear antigen (Figure 4-2). A second 
step that can provide internal validation of an immunostaining protocol is to differentially label 
the positive and negative control cell lines and co-culture them, creating a sample with both 
immunoreactive and unreactive cells (Figure 4-2). 
Using the above methods with stringent controls, we discovered that antibody 8F1 is not 
suitable for measurement of ERCC1 expression because it detects a second antigen 
(Niedernhofer et al., 2007). It has been reported that 8F1 could discriminate between HeLa cells 
and an isogenic strain in which ERCC1 expression was knocked down by siRNA (Olaussen et 
al., 2007). Based on this, it was argued that 8F1 is suitable for measurement of ERCC1 by IHC. 
However, HeLa cells do not have appreciable amount of the non-specific antigen (Figure 4-1D) 
and are thus inappropriate for use as either positive or negative control for validating this 
antibody. In the present work, using formalin-fixed paraffin-embedded normal and ERCC1-XPF 
deficient cell lines, it was confirmed that 8F1 is unable to differentiate between normal and 
ERCC1 deficient cells by IHC (Figure 4-4). Since antibody 8F1 is the most widely used antibody 
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for IHC (Hwang et al., 2008; Kim et al., 2008b; Kwon et al., 2007; Lee et al., 2008; Olaussen et 
al., 2006; Steffensen et al., 2007), it is important to emphasize that it is not specific for ERCC1 
and that validated alternative antibodies exist to reliably measure ERCC1 by IHC. The extensive 
literature on 8F1-IHC does however indicate that the antibody may have prognostic value. This 
warrants further investigation to identify the unknown antigen recognized by 8F1. 
After testing a panel of antibodies raised against ERCC1 and XPF, antibodies suitable for 
a variety of immunodetection techniques were identified (Table 4-1). Most of these are 
unsuitable for IHC, primarily because they do not discriminate between positive and negative 
controls in fixed material. Those that do work (FL297, 4H4, 3F2) should facilitate the intense 
interest in measuring ERCC1 expression in tumor samples by IHC. These are validated 
alternatives to 8F1 that can be used to reliably measure ERCC1 and XPF by IHC. FL297 and 
3F2 were used to measure ERCC1 and XPF, respectively, in lung tumor sections (Figure 4-6). 
Variable levels of cytoplasmic staining were seen in paraffin embedded cell lines (Figure 4-5). 
This staining does not correlate with the level of ERCC1-XPF in cells, nor their sensitivity to 
genotoxic stress. It should therefore be noted that when using these antibodies, grading of 
expression levels should be based on the extent of nuclear staining only. The levels of both 
proteins vary between specimens, ranging from intense staining to virtually no staining, but 
parallel one another (Figure 4-6). This indicates that either ERCC1 or XPF might serve as a 
biomarker of DNA repair in tumors. There was also differential expression within a tumor 
depending on the cell type. These results indicate that measuring ERCC1-XPF may be of value 
for stratifying patients for responsiveness to therapy. 
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5.0  MEASUREMENT OF ERCC1-XPF EXPRESSION IN OVARIAN CARCINOMA 
5.1 INTRODUCTION 
Ovarian carcinoma is the fifth most common cause of cancer deaths in women in the US. The 
death rate from ovarian carcinoma has remained relatively unchanged for last five decades. More 
than two-thirds of patients have advanced stage disease at the time of diagnosis (Jemal et al., 
2008). Primary therapy for these patients consists of debulking surgery followed by platinum-
based chemotherapy (Vergote et al., 2008). Of these women, approximately 25% are either 
refractory to chemotherapy or recur within 6 months of therapy, and usually die within 18 
months (McGuire et al., 1996; Ozols et al., 2003; Piccart et al., 2000). In effect these patients 
receive ineffective therapy that contributes further to their morbidity, lowering their quality of 
life. There is no way to predict the resistance to chemotherapy in these patients.  
The cytotoxicity of platinum-based compounds is mediated through DNA monoadducts, 
and intrastrand and interstrand crosslinks (Rabik and Dolan, 2007). ERCC1-XPF functions in 
both DNA repair pathways required to repair this DNA damage, NER (Sijbers et al., 1996a) and 
ICL repair (De Silva et al., 2000). It is logical to hypothesize that ERCC1-XPF levels are 
predictive of resistance to platinum-based chemotherapy and by extension, treatment outcome. 
Measurement of the levels of ERCC1 and XPF mRNA and protein in ovarian carcinoma 
specimens showed a wide range of expression among tumors. It was found that expression of 
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ERCC1 and XPF mRNA is closely correlated, as is that of the respective proteins. However, for 
both proteins, the levels of mRNA do not correlate to the levels of protein. This suggests that the 
protein levels are regulated at translational and/or post-translational levels.  
5.2 RESULTS AND CONCLUSIONS 
5.2.1 Levels of ERCC1 and XPF mRNA show wide variation 
Measurement of mRNA levels from tumor samples revealed a wide range of expression. The 
median level of ERCC1 mRNA was 6.02 (range: 0.91 – 79.89; 25th – 75th percentile: 2.58 – 
11.55) (Figure 5-1) and the median level of XPF mRNA was 1.27 (range: 0.27 – 5.98; 25th – 75th 
percentile: 0.81 – 2.64) (Figure 5-2). 
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ERCC1 mRNA levels in tumors were measured by qPCR. ERCC1 mRNA levels are plotted on the Y-




Figure 5-2: Tumor XPF mRNA levels 
XPF mRNA levels in tumors were measured by qPCR. XPF mRNA levels are plotted on the Y-axis 
and the tumor identifiers are arranged on the X-axis in an increasing order of the levels of mRNA expression. 
 
5.2.2 ERCC1 and XPF mRNA levels are correlated 
The levels of ERCC1 and XPF mRNA show strong positive correlation (Figure 5-3). Statistical 
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Figure 5-3: Correlation between ERCC1 and XPF mRNA levels 
Levels of ERCC1 and XPF mRNA show strong correlation. XPF mRNA levels are plotted on the Y 
axis and ERCC1 mRNA levels are on the X-axis. 
ERCC1 and XPF protein levels vary widely 
Immunoblots of proteins extracted from the ovarian tumor samples showed a large variation in 
levels of ERCC1 and XPF protein levels among tumors (Figure 5-4). The band intensity anaysis 
revealed more than 12-fold difference in XPF between tumors with the lowest and the highest 
XPF levels, and more than 5-fold difference ERCC1 between tumors with the lowest and the 
highest ERCC1 levels (Figure 5-5). The ratio of ERCC1 to XPF however, remained relatively 
constant (Figure 5-5). The levels of ERCC1 and XPF proteins showed a strong positive 
correlation (Figure 5-6) further showing that ERCC1 and XPF exist as a tightly bound 
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Figure 5-4: Immunoblot for ERCC1 and XPF 
Ovarian tumor lysates were blotted for ERCC1 and XPF. Actin is the loading control. A selection of 
samples showing a range of protein expressions is shown. 
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Immunoblot band intensities of ERCC1 and XPF proteins were corrected with actin loading control 
and plotted on the Y-axis with tumor identifiers on the X-axis. The blue line represents the ratio between 
ERCC1 and XPF levels. 
 
 
Figure 5-6: Correlation between levels ERCC1 and XPF in ovarian tumors 
Levels of ERCC1 and XPF proteins show strong positive correlation. Actin-corrected ERCC1 
protein levels are plotted on the Y-axis and corrected XPF protein levels are on the X-axis. 
5.2.3 Protein levels do not correlate with mRNA levels 
Tumors were charted in increasing order of the ERCC1 mRNA expression. Corresponding 
ERCC1 protein levels did not show a pattern matching that of the mRNA levels (Figure 5-7). 
Charting the XPF mRNA and protein levels in a similar fashion failed to reveal any correlation 
between the two (Figure 5-8). This shows that a change in mRNA levels does not translate into a 
protein level change for either of these proteins. It is likely that ERCC1-XPF protein levels are 
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Figure 5-7: Correlation between ERCC1 protein and mRNA levels 
ERCC1 protein and mRNA levels show no correlation. Actin-corrected ERCC1 protein levels are 
charted on the primary vertical axis, whereas ERCC1 mRNA levels are charted on the secondary vertical 
axis. 
 
Figure 5-8: Correlation between XPF protein and mRNA levels 
XPF protein and mRNA levels show no correlation. Actin-corrected XPF protein levels are charted 
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In conclusion, for both ERCC1 and XPF, the mRNA levels do not reflect the protein 
levels. Therefore, mRNA levels cannot be used as an indicator of protein expression of either 
ERCC1 or XPF. The expression of ERCC1 and XPF is closely correlated and therefore one can 
be used as a surrogate for the other. 
It remains to be known if the levels of either protein or mRNA have any effect on the 
patient outcome and survival. This will be done by categorizing the tumors according to clinical 
outcome and drug resistance. 
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6.0  CONCLUSIONS 
ERCC1 and XPF form a stable complex that acts as a structure-specific endonuclease (Sijbers et 
al., 1996a). Ercc1 and Xpf mutant mice and patients have a phenotype of premature aging that 
differs significantly from other NER-deficient counterparts (Niedernhofer et al., 2006; Tian et 
al., 2004). This difference in phenotypes is explained by the role of ERCC1-XPF in DNA repair 
mechanisms distinct from NER, such as ICL repair (Niedernhofer et al., 2004).  
Although it is known that ERCC1-XPF is required for crosslink repair, it was not known 
whether or how it interacts with another group of proteins that is very important for crosslink 
repair, the FA proteins. All FA proteins except FANCM-FAAP24 and FANCJ lack the ability to 
manipulate DNA. FANCM-FAAP24 and FANCJ do not possess nuclease activity required to 
excise the crosslink from the DNA (Ali et al., 2009). It followed therefore that some nuclease, 
potentially ERCC1-XPF had to play a role in this pathway. As it is shown here, that was indeed 
the case (Bhagwat et al., 2009a). This is an important finding, because it explains how nuclease 
processing of ICL occurs in the FA pathway. In addition, the FANCD2 monoubiquitination and 
chromatin localization events, which were thought to be simultaneous could be dissected and 
shown to be separate, which explains why without ERCC1-XPF, the DSBs produced during ICL 
repair cannot be resolved even though HRR-mediating proteins, such as RAD51 begin to localize 
to the site of damage (Al-Minawi et al., 2009). This work also provides a clear evidence that the 
activation of the FA pathway by FANCD2 monoubiquitination can occur in the absence of both 
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ERCC1-XPF and EME1-MUS81, and therefore is independent of both DSB formation and ICL 
unhooking. This also means that blocked replication forks are probably sufficient for activation 
of ATR and the subsequent phosphorylation of proteins in the FA pathway. The mammalian ICL 
repair pathway has remained elusive due to the involvement of a wide array of DNA repair 
proteins, confounding the picture. By linking the nuclease component with the signaling and 
homologous recombination component of the mechanism, the model has made a definite forward 
progress. It is very important to elucidate this pathway as it has important contribution to the 
processes of cancer and aging. 
Although we know that ERCC1-XPF deficiency causes a deficit in a variety of DNA 
repair pathways, the pleiotropy of these genes makes it difficult to interpret the phenotypes they 
present. It was found that XPF with mutations seen in some severe cases of XP-F and XFE still 
retained some amount of nuclease activity. This did not explain the severity of phenotype seen in 
the patients. It was found by cellular fractionation and immunofluorescence that these mutant 
proteins are unable to enter the nucleus. The mutant proteins are probably misfolded and 
therefore mislocalize to the cytoplasm. Indeed, microinjection of mutant proteins directly into the 
nucleus of ERCC1-XPF deficient cells corrected the phenotype of reduced UV-UDS in these 
cells. This revealed the role of proper folding and localization of proteins in the ERCC1-XPF 
deficiency phenotype. This also means that other genes such as those involved in protein folding 
and nuclear transport can affect the end result of an XPF mutation. This would explain the 
variation in disease severity in patients harboring the same mutation of XPF. 
XP is a rare disease, with a 1 in 250,000 incidence in the US and Europe (Robbins et al., 
1974). This shows the importance of NER proteins to normal cell physiology. Due to the role of 
these proteins in prevention of mutagenesis and genomic instability, it is likely that they are 
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important for both the causation and progression of cancers. One may hypothesize that people 
with lower levels of NER and other DNA repair pathways would be more susceptible to 
oncogenesis through both endogenous and exogenous genotoxic stress. Also, tumors that express 
higher levels of DNA repair factors may be more resistant to genotoxic agents used to treat 
cancers, than tumors expressing lower levels of the same. If that were true, measurement of the 
levels of DNA repair proteins in tumors could be an invaluable tool in our battle against cancer. 
With the ability to predict whether or not a certain patient will respond to a specific treatment, it 
would be possible to devise personally tailored therapies that would improve survival outcome 
and quality of life for cancer patients. To test these hypotheses, it is of paramount importance 
that we develop tools for accurate measurement of DNA repair proteins. Immunohistochemistry 
has been traditionally used as a semi-quantitative method for measurement of biomarkers in 
tumors. However, this methodology is plagued with multiple variables that need to be carefully 
addressed before applying IHC to any study as a quantitative technique (Taylor and Levenson, 
2006). 
We have elaborated a rigorous approach to standardizing measurement of ERCC1 and 
XPF in tumors. Antibodies that could specifically detect ERCC1 and XPF in tumors with the 
ability to discriminate between different levels of these proteins have been found. Studies are 
now in progress to evaluate the possibility that ERCC1 and/or XPF may be predictive of tumor 
resistance or outcome. These studies will cover types of cancers that are treated with platinum-
based chemotherapy including ovarian carcinoma, lung carcinoma and squamous cell carcinoma 
of head and neck. It remains to be seen if these proteins are indeed the useful tumor biomarkers 
they were hypothesized to be. 
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APPENDIX  
LIST OF COMMON ABBREVIATIONS 
AP site Apurinic/apyrimidinic site 
COFS Cerebro-occulo-facio-skeletal syndrome 
DSB Double strand break 
ERCC1 Excision repair cross-complementing rodent repair deficiency group 1 
FA Fanconi anemia 
HN2 Nitrogen mustard 
HRR Homologous recombination repair 
ICL Interstrand crosslink 
IR Ionizing radiation 
MMC Mitomycin C 
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MMEJ Microhomology-mediated end joining 
NER Nucleotide excision repair 
NHEJ Non-homologous end joining 
NSCLC Non-small cell lung carninoma 
SNP Single nucleotide polymorphism 
SSA Single strand annealing 
XFE XPF-ERCC1 progeroid syndrome 
XP Xeroderma pigmentosum 
XP-F Xeroderma pigmentosum complementation group F 
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